symbol
stringlengths 1
5
| body
stringlengths 70
87.5k
| publisher
stringlengths 3
31
| publish_time
unknown | title
stringlengths 7
494
| url
stringlengths 53
141
| uuid
stringlengths 36
36
|
|---|---|---|---|---|---|---|
A | Vipshop Holdings Limited VIPS is set to report first-quarter 2023 results on May 23.VIPS expects first-quarter total net revenues between RMB 25.2 billion and RMB 26.5 billion, indicating growth of 0-5% from the prior-year quarter’s reported figure.The Zacks Consensus Estimate for revenues is pegged at $3.77 billion, suggesting a decline of 5.3% from the year-ago reported figure.The consensus mark for earnings per share is pegged at 39 cents per share, indicating growth of 18.2% from the prior-year reported figure.Vipshop’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average earnings surprise being 22.91%.Vipshop Holdings Limited Price and EPS SurpriseVipshop Holdings Limited Price and EPS SurpriseVipshop Holdings Limited price-eps-surprise | Vipshop Holdings Limited QuoteKey Factors at PlayVipshop’s growing efforts to strengthen product offerings and improve product procurement are expected to have benefited its first-quarter performance.Solid execution of Vipshop’s merchandising strategy is likely to have bolstered its total active customer base in the to-be-reported quarter.VIPS’ quarterly results are expected to reflect its deepening focus on high-margin apparel-related businesses, especially the discount apparel business.The business is expected to have accelerated Vipshop’s gross merchandise volume (GMV) in the quarter under review.Additionally, its successful transition to discount retailing remains a major positive. This is anticipated to have continued driving the momentum across repeated customers and helped attract new ones.VIPS’ deep discount channels are expected to have bolstered its online GMV in the to-be-reported quarter.However, weakening consumer demand in discretionary categories due to the challenging macroenvironment in China might have been a negative.Also, the impacts of intensifying competition in the online shopping market are anticipated to get reflected in the upcoming results of Vipshop.Story continuesWhat Our Model SaysOur proven model doesn’t conclusively predict an earnings beat for Vipshop this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here, as you see below.Vipshop has a Zacks Rank #2 and an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Stocks to ConsiderHere are some stocks worth considering, as our model shows that they have the right combination of elements to beat on earnings this season.Autodesk ADSK has an Earnings ESP of +1.76% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.ADSK is scheduled to release first-quarter 2024 results on May 25. The Zacks Consensus Estimate for ADSK’s earnings is pegged at $1.55 per share, suggesting a rise of 8.4% year over year.Agilent Technologies A has an Earnings ESP of +0.40% and currently carries a Zacks Rank #2.Agilent Technologies is set to report second-quarter fiscal 2023 results on May 23. The Zacks Consensus Estimate for A’s earnings is pegged at $1.27 per share, implying a 12.4% increase from the prior-year quarter’s reported figure.Costco Wholesale COST has an Earnings ESP of +0.04% and a Zacks Rank #3 at present.COST is scheduled to report third-quarter fiscal 2023 results on May 25. The Zacks Consensus Estimate for COST’s earnings is pegged at $3.32 per share, suggesting an increase of 4.7% from the prior-year quarter’s reported figure.Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportCostco Wholesale Corporation (COST) : Free Stock Analysis ReportAutodesk, Inc. (ADSK) : Free Stock Analysis ReportVipshop Holdings Limited (VIPS) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research | Zacks | "2023-05-18T16:14:04" | Vipshop (VIPS) to Post Q1 Earnings: What's in the Offing? | https://finance.yahoo.com/news/vipshop-vips-post-q1-earnings-161404714.html | 27293957-38d0-3710-8e36-c33a88428202 |
A | SANTA CLARA, Calif., May 19, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A), announced today the company intends to appeal the U.S. Patent and Trademarks Office (USPTO) Patent Trial and Appeal Board’s (PTAB) Final Written Decision in connection with the Inter Partes review (IPR) of U.S. Patent Nos. 10,337,001 & 10,900,034 (the Agilent Patents). The PTAB recently reversed the USPTO’s original decision granting claims directed towards chemically modified synthetic CRISPR guide RNA.Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination. The work presented in the two Agilent Patents is also discussed in a publication as part of a broader collaboration with Stanford University in the widely cited paper: Hendel, Ayal et al. "Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells." Nature biotechnology vol. 33,9 (2015): 985-989. doi:10.1038/nbt.3290.The Agilent Patents describe synthesis and testing of hundreds of chemically modified CRISPR guide RNA molecules that were shown to improve the efficiency of CRISPR-based gene editing. Prior to the work done by Agilent’s inventors, it was not known whether the many chemical modifications Agilent made to the various and long guide RNAs would disrupt functionality of the gRNA:Cas enzyme complex. That answer was discovered and disclosed by the Agilent inventors as a multidisciplinary team and using Agilent’s own patented chemical synthesis methods.Building upon its years of expertise in nucleic acid synthesis, Agilent offers the scientific community both research-grade and cGMP-grade guide RNA products incorporating chemical modifications. Agilent’s SureGuide research-grade gRNA products are made and sold in Agilent’s production facility in Santa Clara, California. Agilent’s Nucleic Acid Solutions Division makes and sells its large-scale, cGMP-grade ClinGuide products in its state-of-the art production facilities headquartered in Boulder, Colorado.Story continuesAgilent is confident in the innovative contributions made by its scientists and intends to appeal to the United States Court of Appeals for the Federal Circuit. This patent family also remains open with ongoing prosecution of new claims. Agilent’s Patents will persist until all appeals have been exhausted, and the PTAB decision does not affect Agilent’s continued leadership in CRISPR technologies as a provider of superior-quality guide RNAs. The PTAB’s decision in no way affects Agilent’s ability to make or sell chemically modified gRNA guides.About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005808/en/ContactsINVESTOR CONTACT:Parmeet Ahuja+1 408 345 8948Parmeet_Ahuja@agilent.comMEDIA CONTACT:Sarah LittonAgilent Technologies+1 669 255 7696sarah.litton@agilent.com | Business Wire | "2023-05-19T01:25:00" | Agilent to Appeal Patent Office Decision on CRISPR gRNA Patents | https://finance.yahoo.com/news/agilent-appeal-patent-office-decision-012500775.html | 5477d2fd-f0e0-3721-aeb5-9e4184af5fc1 |
A | Agilent Technologies A is set to report its second-quarter fiscal 2023 results on May 23.For the fiscal second quarter, A expects revenues of $1.655-$1.680 billion, suggesting growth between 6% and 7.5% on a core basis from the year-ago fiscal quarter’s actuals. The Zacks Consensus Estimate for the same is pegged at $1.67 billion, implying growth of 3.8% from the year-ago fiscal quarter’s reported figure.Agilent’s non-GAAP earnings are expected to be $1.24-1.27 per share. The Zacks Consensus Estimate for earnings is pegged at $1.27 per share, indicating growth of 12.4% from the year-ago fiscal quarter’s reported figure.Agilent’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average being 7.03%.Agilent Technologies, Inc. Price and EPS SurpriseAgilent Technologies, Inc. Price and EPS SurpriseAgilent Technologies, Inc. price-eps-surprise | Agilent Technologies, Inc. QuoteKey Factors to NoteAgilent’s performance in the fiscal second quarter is likely to have benefited from solid momentum in the chemical & advanced materials markets.Additionally, A’s strength in the Life Sciences & Applied Markets Group (LSAG) segment, owing to growth in Spectra business and strengthening spectroscopy base across various end markets, is expected to have contributed to its performance in the quarter under review.The Zacks Consensus Estimate for LSAG is pegged at $938 million, implying growth of 4.7% from the year-ago fiscal quarter’s reported figure.Moreover, during the fiscal second quarter, Agilent’s Cross Lab Group (ACG) segment is likely to have benefited from service business growth on the back of strong customer-lab operations.The Zacks Consensus Estimate for ACG is pegged at $367 million, implying growth of 3.96% from the year-ago fiscal quarter’s reported figure.Agilent’s Strength in NASD and Genomics portfolio is likely to have contributed to the Diagnostics and Genomics Group (DGG) segment in the second quarter.The Zacks Consensus Estimate for DGG is pegged at $362 million, implying growth of 1.1% from the year-ago fiscal quarter’s reported figure.Further, strength in the Americas region and growth in the European businesses are expected to have remained tailwinds in the quarter under discussion.However, mounting expenses and macroeconomic headwinds are likely to have remained a headwind in the quarter under review.Story continuesWhat Our Model SaysOur proven model predicts an earnings beat for Agilent. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP FilterAgilent has an Earnings ESP of +0.40% and a Zacks Rank #3 at present.Other Stocks to ConsiderHere are some stocks worth considering as our model shows that these have the right combination of elements to beat on earnings this season.Autodesk ADSK has an Earnings ESP of +1.76% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.ADSK is scheduled to release first-quarter 2024 results on May 25. The Zacks Consensus Estimate for ADSK’s earnings is pegged at $1.55 per share, suggesting a rise of 8.4% year over year.NVIDIA NVDA has an Earnings ESP of +2.43% and carries a Zacks Rank #3 at present.NVDA is slated to report first-quarter fiscal 2024 results on May 24. The Zacks Consensus Estimate for NVDA’s first-quarter earnings is pegged at 92 cents per share, indicating a year-over-year decline of 32.4%.Costco Wholesale COST has an Earnings ESP of +0.04% and a Zacks Rank #3 at present.COST is scheduled to report third-quarter fiscal 2023 results on May 25. The Zacks Consensus Estimate for COST’s earnings is pegged at $3.32 per share, suggesting an increase of 4.7% from the prior-year quarter’s reported figure.Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportNVIDIA Corporation (NVDA) : Free Stock Analysis ReportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportCostco Wholesale Corporation (COST) : Free Stock Analysis ReportAutodesk, Inc. (ADSK) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research | Zacks | "2023-05-19T15:08:03" | Agilent Technologies (A) to Post Q2 Earnings: What's in Store? | https://finance.yahoo.com/news/agilent-technologies-post-q2-earnings-150803307.html | 619f9fb9-c102-37fc-8b8c-50c11237b9a7 |
A | Earnings reports from Zoom Video, Lowe’s, Snowflake, Best Buy, Costco, and Ulta. Plus, minutes from the Federal Reserve’s May meeting and core PCE inflation data.Continue reading | Barrons.com | "2023-05-21T19:00:00" | Costco, JPMorgan, Snowflake, Ford, Zoom, and More Stocks to Watch This Week | https://finance.yahoo.com/m/5f7a781e-1e0c-30b0-a052-1d88fc0ce184/costco-jpmorgan-snowflake-.html | 5f7a781e-1e0c-30b0-a052-1d88fc0ce184 |
A | Agilent Technologies A reported second-quarter fiscal 2023 earnings of $1.27 per share, which came in line with the Zacks Consensus Estimate. The bottom line increased by 12.4% from the year-ago fiscal quarter’s level.Revenues of $1.72 billion surpassed the Zacks Consensus Estimate of $1.67 billion. The top line was up 6.8% on a reported basis and 9.5% on a core basis from the respective year-ago fiscal quarter’s levels.Top-line growth was driven by strong momentum across Food, Academia & Gov’t and Chemistry & Advanced Materials markets. A strong performance in China also contributed well.Segmental Top Line DetailsAgilent has three reporting segments, namely, Life Sciences & Applied Markets Group (LSAG), Agilent Cross Lab Group (ACG) and Diagnostics and Genomics Group (DGG).LSAG: The segment accounted for $968 million or 56% of its total revenues, up 8% on a reported basis and 10% on a core basis from the respective prior-year fiscal quarter’s levels. This was driven by strong performance in the Chemical & Advanced Materials, Food and Academic & Gov’t markets. Strength in LC and LCMS and lab consumables also aided results.ACG: Revenues from the segment were $387 million, accounting for 23% of total revenues. Also, the top line improved by 10% from the prior-year fiscal quarter’s reading on a reported basis and 13% on a core basis, driven by strength in services attached to new instrument installations as well as expanding service offerings for the existing instrument base.DGG: Revenues increased 1% from the prior-year fiscal quarter’s figure on a reported basis and 3% on a core basis to $362 million, accounting for the remaining 21% of total revenues. Segmental growth was attributed to strength in the NASD and pathology businesses. Also, solid momentum in companion diagnostics pharma services contributed well.Agilent Technologies, Inc. Price, Consensus and EPS SurpriseAgilent Technologies, Inc. Price, Consensus and EPS SurpriseAgilent Technologies, Inc. price-consensus-eps-surprise-chart | Agilent Technologies, Inc. QuoteStory continuesOperating ResultsFor the fiscal second quarter, gross margin in the LSAG segment expanded by 90 basis points (bps) to 59.9% from the prior-year fiscal quarter’s number. ACG’s gross margin contracted 10 bps to 47%. DGG’s gross margin contracted 420 bps from the year-ago fiscal quarter’s actuals to 51.8%.Research & development (R&D) costs were $126 million, up 9.6% from the prior-year fiscal quarter’s number. Selling, general & administrative (SG&A) expenses were $415 million, up 7.5% from the year-earlier fiscal quarter’s figure. As a percentage of revenues, R&D expenses expanded 10 bps year over year to 7.3%. Meanwhile, SG&A expenses expanded 20 bps year over year to 24.2%.Operating margin for the fiscal first quarter was 22.3%, which contracted 10 bps from the year-earlier fiscal quarter’s figure.Segment-wise, the operating margin for LSAG was up 180 bps from the year-earlier fiscal quarter’s level of 27.3%. ACG’s operating margin was 26.6%, up 200 bps from the year-ago fiscal quarter’s level. DGG segment’s operating margin contracted 530 bps to 20.2% from the year-ago fiscal quarter’s figure.Balance Sheet & Cash FlowAs of Apr 30, 2023, Agilent’s cash and cash equivalents were $1.18 billion, down from $1.25 billion on Jan 31, 2023.Accounts receivables were $1.4 billion at the end of second-quarter fiscal 2023, down from $1.5 billion at the end of first-quarter fiscal 2023.Long-term debt was $2.733 billion for the reported quarter, which remained flat as compared with the prior fiscal quarter.Agilent generated $398 million in cash from operations during the reported quarter, up from $296 million generated in the previous quarter.Further, it returned $151 million to shareholders, out of which dividend payments accounted for $66 million and share repurchases accounted for the remaining $85 million.GuidanceFor the fiscal third quarter of 2023, management expects revenues of $1.640-$1.675 billion, suggesting growth between 4.5% and 2.5% on a core basis from the year-ago fiscal quarter’s actuals. The Zacks Consensus Estimate for the same is pegged at $1.76 billion.Non-GAAP earnings per share are expected to be $1.36-$1.38. The consensus mark for fiscal third-quarter earnings stands at $1.43 per share.For fiscal 2023, management lowered its revenue guidance from the band of $7.03-$7.1 billion to $6.93-7.03 billion, implying a growth of 1.2-2.7% on a reported basis and 3-4.5% on a core basis from the respective fiscal 2022 figures. The Zacks Consensus Estimate for the same is pegged at $7.07 billion.Management also updated the guidance for fiscal 2023 non-GAAP earnings per share downward from $5.65-$5.70 to $5.60-$5.65. The consensus mark for fiscal 2023 earnings is pegged at $5.68 per share.Zacks Rank & Other Stocks to ConsiderCurrently, Agilent carries a Zacks Rank #3 (Hold).Investors interested in the broader technology sector can consider some better-ranked stocks like Ciena CIEN, CrowdStrike CRWD and AMETEK AME. Ciena, CrowdStrike and AMETEK each carry a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Ciena shares have lost 14.9% in the year-to-date time frame. The Zacks Consensus Estimate for CIEN’s fiscal year 2023 earnings is pegged at $2.81 per share, suggesting an increase of 47.9% from the prior year’s reported figure.CrowdStrike shares have risen 27% in the year-to-date period. The Zacks Consensus Estimate for CRWD’s 2023 earnings is pegged at $2.30 per share, suggesting growth of 49.4% from the prior year’s reported figure.AMETEK shares have rallied 3.4% year to date. The Zacks Consensus Estimate for AME’s 2023 earnings is pegged at $6.11 per share, suggesting an increase of 7.57% from the prior year’s reported figure.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportCiena Corporation (CIEN) : Free Stock Analysis ReportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportAMETEK, Inc. (AME) : Free Stock Analysis ReportCrowdStrike (CRWD) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research | Zacks | "2023-05-24T17:17:00" | Agilent (A) Q2 Earnings Match Estimates, Revenues Rise Y/Y | https://finance.yahoo.com/news/agilent-q2-earnings-match-estimates-171700417.html | e9307f15-4308-33d8-a649-57f4df3530b1 |
A | Retailers Kohl's and Abercrombie deliver profit surprises, Sarepta Therapeutics says the FDA has delayed a decision date on its gene therapy, and guidance from Analog Devices disappoints.Continue reading | Barrons.com | "2023-05-24T20:11:00" | These Stocks Are Moving the Most Today: Kohl’s, Abercrombie, Urban Outfitters, Sarepta, Analog Devices, and More | https://finance.yahoo.com/m/371cc8aa-e61a-3a35-8561-bbaa00ca4589/these-stocks-are-moving-the.html | 371cc8aa-e61a-3a35-8561-bbaa00ca4589 |
A | *White House, Republicans resume US debt ceiling talks*Stocks hold declines after release of Fed minutes*Citigroup drops after scrapping Mexico unit sale*Indexes down: Dow 0.77%, S&P 0.73%, Nasdaq 0.61%(Adds official closing market details throughout)By Lewis Krauskopf, Shreyashi Sanyal and Shristi Achar AMay 24 (Reuters) - Wall Street's main indexes ended lower on Wednesday as talks between the White House and Republican representatives on raising the U.S. debt ceiling dragged on without a deal.The lack of progress on raising the U.S. government's $31.4 trillion debt limit ahead of a June 1 deadline, with several rounds of inconclusive talks, has made investors edgier as the risk of a catastrophic default looms larger.Democratic President Joe Biden and top congressional Republican Kevin McCarthy's negotiators held what the White House called productive talks."Up until yesterday, investors have been very optimistic around the U.S. debt ceiling resolution," said Angelo Kourkafas, senior investment strategist at Edward Jones. "But now as we get closer ... to the June 1st X-date, we are seeing some caution again.”The Dow Jones Industrial Average fell 255.59 points, or 0.77%, to 32,799.92, the S&P 500 lost 30.34 points, or 0.73%, to 4,115.24 and the Nasdaq Composite dropped 76.08 points, or 0.61%, to 12,484.16.Ten of the 11 S&P 500 sectors ended in negative territory, with real estate falling the most. Energy was the lone sector gainer.The CBOE Volatility Index, known as Wall Street's fear gauge, hovered around three-week highs.Federal Reserve policy was also in focus. Stocks held their declines after the release of minutes from the Fed's May 2-3 meeting, showing that Fed officials "generally agreed" last month that the need for further interest rate increases "had become less certain."Investors expect the central bank to pause its aggressive rate hiking campaign at its June 13-14 meeting.Story continuesFed Governor Christopher Waller said he is concerned about the lack of progress on inflation, and while skipping an interest rate hike at the central bank's meeting next month may be possible, an end to the hiking campaign is not likely.“The economy is still doing OK, and there really is not, from the Fed’s perspective, a reason to back away from a tighter monetary policy,” said Paul Nolte, senior wealth advisor and market strategist at Murphy & Sylvest Wealth Management.In company news, Citigroup Inc shares fell 3.1% as the bank scrapped a $7 billion sale of its Mexican consumer unit Banamex and will list it instead.Agilent Technologies Inc shares shed about 6% after the company cut its annual sales and profit forecasts.Shares of TurboTax-owner Intuit Inc dropped 7.5% after a disappointing profit forecast.Declining issues outnumbered advancing ones on the NYSE by a 3.71-to-1 ratio; on Nasdaq, a 2.34-to-1 ratio favored decliners.The S&P 500 posted no new 52-week highs and 14 new lows; the Nasdaq Composite recorded 38 new highs and 110 new lows.About 9.7 billion shares changed hands in U.S. exchanges, compared with the 10.5 billion daily average over the last 20 sessions. (Reporting by Lewis Krauskopf and Sinéad Carew in New York, Shreyashi Sanyal and Shristi Achar A in Bengaluru Editing by Vinay Dwivedi and David Gregorio) | Reuters | "2023-05-24T20:16:53" | US STOCKS-Wall St ends down as debt-ceiling clouds hover | https://finance.yahoo.com/news/us-stocks-wall-st-ends-201653651.html | 1eeea160-b463-372c-b344-85ef6fb3a4d8 |
A | In this article, we discuss 15 growth stocks to watch in Louis Navellier's 2023 portfolio. If you want to see more stocks in this selection, check out Louis Navellier's 2023 Portfolio: 5 Growth Stocks to Watch. According to a report featured on Markets Insider in October 2022, Louis Navellier of Navellier & Associates said that the S&P 500 is on the verge of significant changes in the upcoming years, with energy stocks gaining increased attention from investors. Navellier predicted that this upward trend will persist, estimating that the energy sector may make up around 30% of the S&P 500 by 2025. This would mark a remarkable surge for an industry that has been overlooked by investors focused on environmental, social, and governance (ESG) factors in recent times. This shift would come at the cost of the technology sector, which, along with communication services, accounted for nearly half of the S&P 500 at its highest point during the pandemic. Navellier said: "I predict that in early 2025, energy stocks will be 30% of the S&P 500 and technology stocks will fall to about only 32%. Tracking managers will be systematically buying energy stocks and a net seller of technology stocks as the sector weights in the S&P 500 change for at least the next couple of years." In an interview with Fox Business on February 21, 2023, Navellier expressed agreement with the idea that the average consumer is facing challenges. He mentioned that the only retailer in his portfolio is Costco Wholesale Corporation (NASDAQ:COST), which he described as more of a luxury goods company that also sells gasoline in large quantities. Navellier pointed out that consumers are under pressure, citing The Home Depot, Inc. (NYSE:HD) and Walmart Inc. (NYSE:WMT) as examples of consumer-focused companies reporting gloomy financial results. During the Fox interview, he commented on the inflated job numbers in January resulting from seasonal patterns and voiced his belief that the labor market will undergo a significant readjustment in the next five months, offering a more accurate and realistic perspective. Navellier also communicated uncertainty about the accuracy of both the job numbers and the sales report for the month of January, as he found discrepancies and believed the figures were significantly inflated. He observed that the combination of seasonal effects, treasury yields, and inflation data failed to provide a satisfactory explanation for the January figures. Nevertheless, he displayed a lack of concern regarding inflation, as his portfolio experienced strong performance primarily due to the presence of plentiful energy stocks.Story continuesLouis Navellier is recognized as a growth-oriented investor who specializes in identifying companies with robust growth potential. Some of the top growth stocks to watch in Navellier's portfolio include NVIDIA Corporation (NASDAQ:NVDA), Enphase Energy, Inc. (NASDAQ:ENPH), and Novo Nordisk A/S (NYSE:NVO). Our Methodology This list consists of growth stocks that Louis Navellier's Navellier & Associates held during the first quarter of 2023. By growth stocks we mean companies operating in growth-oriented industries such as tech, electric vehicles, fintech, ecommerce, biotech and healthcare, and renewable energy. The list is ranked in ascending order of dollar value of the hedge fund's stakes in these companies. We have also mentioned the hedge fund sentiment around the securities as of Q1 2023. Louis Navellier's 2023 Portfolio: 15 Growth Stocks to WatchLouis Navellier of Navellier & AssociatesLouis Navellier's 2023 Portfolio: Growth Stocks to Watch15. Axcelis Technologies, Inc. (NASDAQ:ACLS)Stake Value of Navellier & Associates: $2,389,039Number of Hedge Fund Holders: 34Axcelis Technologies, Inc. (NASDAQ:ACLS) is involved in the creation, production, and maintenance of ion implantation and additional processing machinery utilized in the manufacturing of semiconductor chips across the United States, Europe, and Asia Pacific. In Q1 2023, Louis Navellier's fund held 17,929 shares of Axcelis Technologies, Inc. (NASDAQ:ACLS) worth $2.38 million. On May 3, Axcelis Technologies, Inc. (NASDAQ:ACLS) reported a Q1 GAAP EPS of $1.43 and a revenue of $254.02 million, topping Wall Street estimates by $0.18 and $14.13 million. Axcelis anticipates generating revenues in the range of $255 million to 260 million for the second quarter ending on June 30, 2023. This projection compares to the consensus estimate of $250.39 million.According to Insider Monkey’s first quarter database, 34 hedge funds were long Axcelis Technologies, Inc. (NASDAQ:ACLS), compared to 24 funds in the prior quarter. Richard Driehaus’ Driehaus Capital is the largest position holder in the company, with 728,641 shares worth $97 million. Like NVIDIA Corporation (NASDAQ:NVDA), Enphase Energy, Inc. (NASDAQ:ENPH), and Novo Nordisk A/S (NYSE:NVO), Axcelis Technologies, Inc. (NASDAQ:ACLS) is one of the top growth stocks to watch in Louis Navellier's 2023 portfolio. 14. Booz Allen Hamilton Holding Corporation (NYSE:BAH)Stake Value of Navellier & Associates: $2,641,665Number of Hedge Fund Holders: 34Booz Allen Hamilton Holding Corporation (NYSE:BAH) offers a wide range of services including management and technology consulting, analytics, engineering, digital solutions, mission operations, and cyber services in the United States and internationally. In the first quarter of 2023, Navellier held 28,500 shares of Booz Allen Hamilton Holding Corporation (NYSE:BAH) worth $2.64 million. It is one of the top growth stocks in the Navellier portfolio. After being awarded a contract by the IRS for Enterprise Development Operations Services, Booz Allen Hamilton Holding Corporation (NYSE:BAH) received an Overweight rating and a $116 price target from Morgan Stanley on May 5. The investment firm believes that based on the contract size, duration, and competition, this project could generate approximately $100 million in annual revenue, contributing to a growth of around 1% compared to Booz Allen Hamilton Holding Corporation (NYSE:BAH)’s current levels. Additionally, Morgan Stanley highlighted that this contract value might help safeguard some of Booz Allen's existing work with the IRS, which was previously at risk due to the TCloud outcome earlier in 2023.According to Insider Monkey’s first quarter database, 34 hedge funds were long Booz Allen Hamilton Holding Corporation (NYSE:BAH), compared to 36 funds in the prior quarter. Woodline Partners is the biggest stakeholder of the company. 13. Fortinet, Inc. (NASDAQ:FTNT)Stake Value of Navellier & Associates: $3,176,256Number of Hedge Fund Holders: 45Fortinet, Inc. (NASDAQ:FTNT) is a provider of cybersecurity and networking solutions worldwide. The company offers FortiGate hardware and software licenses, which encompass a wide range of security and networking capabilities such as firewall, intrusion prevention, anti-malware, virtual private network, application control, web filtering, anti-spam, and wide area network acceleration. In Q1 2023, Louis Navellier had 47,792 shares of Fortinet, Inc. (NASDAQ:FTNT) in his portfolio, worth $3.17 million and representing 0.66% of the total 13F securities. On May 8, BofA upgraded Fortinet, Inc. (NASDAQ:FTNT) to Buy from Neutral with a price target of $75, up from $66. According to BofA, the company's strong fundamentals and consistent execution in a challenging environment justify a premium compared to its peers in the cybersecurity industry. The firm acknowledged the existence of backlog drawdowns but believes that Fortinet, Inc. (NASDAQ:FTNT)’s business momentum outweighs these concerns, as there is a robust underlying demand that reflects the significant value Fortinet provides to its customers.According to Insider Monkey’s first quarter database, 45 hedge funds were long Fortinet, Inc. (NASDAQ:FTNT), compared to 47 funds in the prior quarter. Andreas Halvorsen’s Viking Global is the biggest stakeholder of the company. Here is what ClearBridge SMID Cap Growth Strategy has to say about Fortinet, Inc. (NASDAQ:FTNT) in its Q3 2021 investor letter:“Performance among our cohort of IT and Internet companies was mixed, with enterprise software makers thriving while more consumer-oriented stocks faced headwinds. Cyber security software maker Fortinet benefited from a heightened awareness of the need to protect against sophisticated attacks. We are attracted to the recurring revenue nature of these software companies that are increasingly delivering their products on a subscription basis through the cloud. Software business models also tend to avoid many of the inflationary issues facing companies with a physical product or service.”12. Apple Inc. (NASDAQ:AAPL)Stake Value of Navellier & Associates: $3,335,432Number of Hedge Fund Holders: 131Louis Navellier's 2023 portfolio had 20,227 shares of Apple Inc. (NASDAQ:AAPL), worth $3.3 million and representing 0.7% of the 13F securities. On May 4, Apple Inc. (NASDAQ:AAPL) announced an additional program to buy back up to $90 billion of its stock.On May 22, Loop Capital downgraded Apple Inc. (NASDAQ:AAPL) to Hold from Buy with an unchanged price target of $180. Apple Inc. (NASDAQ:AAPL) has recently lowered its iPhone production and shipment forecasts for the second time in the past four weeks. The analyst suggests that Apple has reduced its June quarter builds and shipments by approximately 10%, in addition to the reduced guidance provided by the company on May 4. This reduction poses a significant downside risk to Apple's June quarter revenue, both in comparison to its own guidance and the estimates of the Street. Loop Capital also believes that Apple Inc. (NASDAQ:AAPL) has further decreased its estimated iPhone shipments for the June quarter by an additional 5 million units to reach a total of 35 million units.According to Insider Monkey’s fourth quarter database, 131 hedge funds were long Apple Inc. (NASDAQ:AAPL), compared to 135 funds in the earlier quarter. Warren Buffett’s Berkshire Hathaway is the largest stakeholder of the company, with 915.5 million shares worth $151 billion. Alger Spectra Fund made the following comment about Apple Inc. (NASDAQ:AAPL) in its Q1 2023 investor letter:“Apple Inc. (NASDAQ:AAPL) is a leading technology provider in telecommunications, computing, and services. Apple’s iOS operating system is the company’s unique intellectual property and competitive strength. This software drives particularly tight engagement with consumers and enterprises, which is fostering the growing purchase of high margin services like music, apps, and Apple Pay. While iPhone sales were down year-over-year (YoY). services revenues grew 7% YoY which was slightly above analyst estimates. Company earnings were also better-than-anticipated due to lower input costs, such as memory chips and cost control initiatives. Aside from production disruptions, negative sentiment had also weighed on shares as investors questioned how an economic slowdown would affect consumer demand for Apple products in 2023. However, management projected an acceleration in earnings for the fiscal first quarter, where they noted that iPhone and services growth should remain strong, along with encouraging impacts around product mix, lower input costs, and continued cost controls.”11. Agilent Technologies, Inc. (NYSE:A)Stake Value of Navellier & Associates: $3,781,662Number of Hedge Fund Holders: 55Agilent Technologies, Inc. (NYSE:A) offers specialized solutions for life sciences, diagnostics, and applied chemical markets worldwide. Its operations are divided into three main segments – Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. In Q1 2023, Louis Navaellier added Agilent Technologies, Inc. (NYSE:A) to his portfolio by purchasing 27,336 shares worth $3.78 million. On May 23, Agilent Technologies, Inc. (NYSE:A) reported FQ2 non-GAAP EPS of $1.27 and a revenue of $1.72 billion, topping Wall Street estimates by $0.01 and $50 million, respectively. Barclays analyst Luke Sergott initiated coverage of Agilent Technologies, Inc. (NYSE:A) with an Equal Weight rating and a $140 price target on May 11. According to Insider Monkey’s first quarter database, 55 hedge funds were bullish on Agilent Technologies, Inc. (NYSE:A), compared to 48 funds in the prior quarter. William Von Mueffling’s Cantillon Capital Management is the biggest stakeholder of the company. Cooper Investors made the following comment about Agilent Technologies, Inc. (NYSE:A) in its Q4 2022 investor letter:“Agilent Technologies, Inc. (NYSE:A) finished a great year with +12% organic growth after a +15% year in 2021. As a supplier of liquid chromatography/ mass spectrometry instruments into the life sciences industry, Agilent enjoyed a period of supernormal growth over the 2020-2021 COVID pandemic. Like several of our healthcare and diagnostics investments Agilent de-rated quite sharply in the first half of 2022 as the market ‘faded’ the decline in COVID testing revenues. In our view this short term volatility obscures the high quality of Agilent’s business and long term growth opportunities. One example is environmental testing as mandated by the US EPA where US$4bn of funding in the infrastructure bill has been put aside for PFAS testing. As CEO Mike McMullen noted on the last call, ‘it’s the first time in my career we’ve seen this kind of government money coming in’.”10. ExlService Holdings, Inc. (NASDAQ:EXLS)Stake Value of Navellier & Associates: $3,959,171Number of Hedge Fund Holders: 24ExlService Holdings, Inc. (NASDAQ:EXLS) operates globally and specializes in data analytics, digital operations, and providing solutions to different industries. The company is divided into four segments – Insurance, Healthcare, Analytics, and Emerging Business. Securities filings for the first quarter of 2023 reveal that Louis Navellier's hedge fund owned 24,465 shares of ExlService Holdings, Inc. (NASDAQ:EXLS) worth $3.95 million, representing 0.83% of the total 13F securities. It is one of the top growth stocks to watch in Navellier’s portfolio. On April 28, TD Cowen analyst Bryan Bergin raised the firm's price target on ExlService Holdings, Inc. (NASDAQ:EXLS) to $195 from $190 and kept an Outperform rating on the shares. The analyst noted that ExlService Holdings, Inc. (NASDAQ:EXLS) delivered impressive results in the first quarter, surpassing expectations in both Digital Operations and Analytics. The company's resilient value proposition and strong overall momentum have allowed it to overcome challenges in discretionary areas, the analyst wrote in a research note. According to Insider Monkey’s first quarter database, 24 hedge funds were long ExlService Holdings, Inc. (NASDAQ:EXLS), and James Parsons’ Junto Capital Management held the largest stake in the company, comprising 138,123 shares worth $22.35 million. Here is what Bernzott Capital US Small Cap Value Fund has to say about ExlService Holdings, Inc. (NASDAQ:EXLS) in its Q1 2022 investor letter:“ExlService Holdings (NASDAQ:EXLS): After approximately four years of ownership, this provider of offshore business process outsourcing solutions was sold from the portfolio as it achieved fair value. During our period of ownership, the stock almost tripled in value and significantly outperformed the Russell 2000 Value index.”9. Allegro MicroSystems, Inc. (NASDAQ:ALGM)Stake Value of Navellier & Associates: $3,977,891Number of Hedge Fund Holders: 25Allegro MicroSystems, Inc. (NASDAQ:ALGM) specializes in the design, development, manufacturing, and marketing of integrated circuits (ICs). The company’s ICs are specifically designed for sensors and application-specific analog power systems, with a focus on motion control and energy-efficient applications. Allegro MicroSystems, Inc. (NASDAQ:ALGM) was a new arrival in Navellier & Associates’ Q1 2023 portfolio, with the hedge fund buying 82,890 shares valued at $3.97 million. It is one of the top growth stocks to watch in Louis Navellier's portfolio. Following strong financial results in the March quarter, Mizuho analyst Vijay Rakesh increased the price target on Allegro MicroSystems, Inc. (NASDAQ:ALGM) to $50 from $48 and maintained a Buy rating on the shares on May 12. According to Insider Monkey’s first quarter database, 25 hedge funds were bullish on Allegro MicroSystems, Inc. (NASDAQ:ALGM), compared to 15 funds in the earlier quarter. Ken Griffin’s Citadel Investment Group is the largest stakeholder of the company. Artisan Small Cap Fund made the following comment about Allegro MicroSystems, Inc. (NASDAQ:ALGM) in its Q1 2023 investor letter:“Among our top contributors were Lattice Semiconductor, Monolithic Power Systems, Allegro MicroSystems, Inc. (NASDAQ:ALGM), HubSpot and Wingstop. A strong area of the portfolio was our semiconductor holdings as Lattice Semiconductor, Monolithic Power Systems and Allegro Microsystems each outperformed. This is an area of the market where we have historically found many compelling opportunities, and we believe it continues to be an attractive area for long-term capital. Our high-level thesis is that industry consolidation is driving profitability improvements which, combined with top-line demand growth drivers, are breeding many interesting profit cycles. Please read our latest semiconductor industry white paper to dive into our thoughts on the industry. After the strong performance in the quarter, we trimmed Lattice Semiconductor in order to manage the position size and also trimmed Monolithic Power Systems due to the company outgrowing our small-cap mandate.”8. Eli Lilly and Company (NYSE:LLY)Stake Value of Navellier & Associates: $4,475,106Number of Hedge Fund Holders: 72Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical company engaged in the discovery, development, and marketing of pharmaceutical products. In Q1 2023, Louis Navellier owned 13,031 shares of Eli Lilly and Company (NYSE:LLY) worth $4.47 million, representing 0.94% of the 13F securities. It is one of the top growth stocks to watch in Navellier's portfolio. On May 4, BMO Capital raised its price target on Eli Lilly and Company (NYSE:LLY) from $430 to $505 and maintained an Outperform rating on the shares. The firm is optimistic about the potential success of Eli Lilly and Company (NYSE:LLY)’s Donanemab in treating ALZ2, which positions it as a strong competitor to Biogen's Leqembi. This success is seen as an opportunity for investors to benefit from increased share value. BMO Capital has also revised its peak sales estimates for Donanemab, projecting sales of $17 billion, up from the previous estimate of $9.6 billion.According to Insider Monkey’s first quarter database, 72 hedge funds were bullish on Eli Lilly and Company (NYSE:LLY), compared to 76 funds in the earlier quarter. Rajiv Jain’s GQG Partners is the largest stakeholder of the company, with a position worth $1.02 billion. Baron Health Care Fund made the following comment about Eli Lilly and Company (NYSE:LLY) in its Q1 2023 investor letter:“In pharmaceuticals, our largest investment continues to be in Eli Lilly and Company (NYSE:LLY). Lilly’s new diabetes drug Mounjaro is likely to be approved for obesity in 2023. Lilly has two new obesity drugs advancing into Phase 3 trials. Lilly also has a drug in late-stage development for Alzheimer’s disease. Lilly is not facing any significant near-term patent expirations, and we think the company should be able to grow revenue and earnings at attractive rates through the end of the decade and beyond.”7. Arista Networks, Inc. (NYSE:ANET)Stake Value of Navellier & Associates: $4,672,887Number of Hedge Fund Holders: 48Arista Networks, Inc. (NYSE:ANET) specializes in the development, marketing, and sale of cloud networking solutions. Arista Networks, Inc. (NYSE:ANET)’s cloud networking solutions encompass flexible operating systems, a range of network applications, and advanced gigabit Ethernet switching and routing platforms. In Q1 2023, Louis Navellier's fund held 27,838 shares of Arista Networks, Inc. (NYSE:ANET) worth $4.6 million. It is one of the top growth stocks to invest in according to Navaellier. On May 24, Argus analyst Jim Kelleher increased the price target on Arista Networks, Inc. (NYSE:ANET) from $175 to $195 while maintaining a Buy rating on the shares. Kelleher explained that although cloud titan spending is anticipated to decrease in 2023 after experiencing over 100% growth in 2022, Arista Networks, Inc. (NYSE:ANET) is expected to witness improvements in gross margin and operating margins throughout the year. The analyst highlighted that Arista Networks, Inc. (NYSE:ANET) has effectively managed the challenges posed by the supply-chain crisis and is successfully navigating through macroeconomic weaknesses, customer caution, cost inflation, and the digestion of cloud titan inventory. Furthermore, the company has been expanding its range of solutions and increasing its total addressable market, the analyst wrote in a research note. According to Insider Monkey’s first quarter database, 48 hedge funds were bullish on Arista Networks, Inc. (NYSE:ANET), compared to 53 funds in the prior quarter. Steve Cohen’s Point72 Asset Management is the biggest stakeholder of the company. Giverny Capital made the following comment about Arista Networks, Inc. (NYSE:ANET) in its Q1 2023 investor letter:“Our holding Arista Networks, Inc. (NYSE:ANET) continues to generate extraordinary results, which the market recognizes. Arista rose 38% during the first quarter and became our largest holding. Arista makes switches, routers and operating software that power enormous data networks, such as for cloud computing. Microsoft’s Azure cloud business and Meta Platforms’ Facebook and Instagram networks are Arista’s two most important customers. Roughly speaking, Arista has tripled its revenue and profit over the past five years and seems poised to continue growing rapidly for the foreseeable future. Demand for hyperscale computing networks may accelerate as artificial intelligence (AI) chat applications grow. By some estimates, the computer power required to answer Al chat queries is roughly seven times more than for a Google or Bing search. I think the realization that data network capacity needs to be much larger to accommodate Al has driven recent enthusiasm for Arista.In general, I think when a stock blows through my price target the right answer is to bask in the glory and maybe splurge on a latte rather than my usual morning coffee. Don’t get itchy about locking in a profit. In this case, Arista became our largest holding and roughly 8.5% of the portfolio, while also being one of the most expensive businesses we own on a price-to-earnings basis. Arista earned $4.27 in 2022 and I believe there is good reason to expect it to double EPS again, perhaps by 2026 or 2027. But as the stock traded into the $160s, that represents a PE of 20x estimated earnings in four years. While I believe strongly in Arista’s competitive position, I know that tech giants are facing budget constraints and a pause in their own intense pace of infrastructure growth would not surprise anyone….” (Click here to read the full text)6. AbbVie Inc. (NYSE:ABBV)Stake Value of Navellier & Associates: $4,717,671Number of Hedge Fund Holders: 75AbbVie Inc. (NYSE:ABBV) is a pharmaceutical company involved in the discovery, development, manufacturing, and sale of pharmaceutical products across the world. Securities filings for Q1 2023 reveal that Louis Navellier owned 29,602 shares of $4.7 million.On April 28, Guggenheim maintained a Buy rating on AbbVie Inc. (NYSE:ABBV) but slightly lowered its price target on the shares from $172 to $171. Although AbbVie's Q1 results exceeded management guidance and aligned with the firm's estimates, the stock experienced an 8% decline primarily due to weaker performance in key growth drivers Skyrizi and Rinvoq, according to the firm. However, after analyzing management commentary during the conference call and conducting a follow-up call with the team, the firm expressed minimal concern and stated that no changes are being made to their short- or long-term estimates for either product.According to Insider Monkey’s first quarter database, 75 hedge funds were long AbbVie Inc. (NYSE:ABBV), compared to 73 funds in the last quarter. Ken Griffin’s Citadel Investment Group is the largest stakeholder of the company. In addition to NVIDIA Corporation (NASDAQ:NVDA), Enphase Energy, Inc. (NASDAQ:ENPH), and Novo Nordisk A/S (NYSE:NVO), AbbVie Inc. (NYSE:ABBV) is one of the top growth stocks on Louis Navellier's radar. Baron Health Care Fund made the following comment about AbbVie Inc. (NYSE:ABBV) in its Q1 2023 investor letter:“In a difficult quarter during which the Health Care sector failed to participate in the broader market rally, Baron Health Care Fund modestly trailed the Benchmark by 42 basis points, as disappointing stock selection overshadowed favorable impacts from differences in sub-industry weights and cash exposure. Lower exposure to benchmark heavyweight AbbVie Inc. (NYSE:ABBV) and declines in Cytokinetics, Incorporated, Ascendis Pharma A/S, and Inhibrx, Inc. also weighed on performance in the sub-industry. We reduced our position in AbbVie Inc. due to our less optimistic view of the company’s pipeline and long-term growth profile.” Click to continue reading and see Louis Navellier's 2023 Portfolio: 5 Growth Stocks to Watch. Suggested articles:14 Best Biotech Stocks To Buy15 Largest Potash Producing Countries in the World10 Best Value Stocks to Buy in 2023 According to Billionaire Mario Gabelli Disclosure: None. Louis Navellier's 2023 Portfolio: 15 Growth Stocks to Watch is originally published on Insider Monkey. | Insider Monkey | "2023-05-26T19:56:39" | Louis Navellier’s 2023 Portfolio: 15 Growth Stocks to Watch | https://finance.yahoo.com/news/louis-navellier-2023-portfolio-15-195639029.html | 7b650af3-66ff-32ce-a0f2-ee24afb29b53 |
A | Self-aware solutions making mass spectrometry more accessibleSANTA CLARA, Calif., June 02, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced new mass spectrometry solutions on show at the 71st ASMS Conference on Mass Spectrometry and Allied Topics, being held June 4 - 8 in Houston, Texas. Agilent is a global leader in the mass spectrometry market, providing advanced, intelligent instruments featuring improved analytical performance solutions for analytical labs worldwide."Agilent is leading the way in the trend towards developing more self-aware and intelligent instruments," said Sudharshana Seshadri, vice president and general manager of Agilent’s Liquid Chromatography, Mass Spectrometry, and Automation Divisions. "Our goal is to make our customers’ lives easier, so they worry less about their instruments and can focus more on their science."New products will be highlighted at ASMS that add to Agilent’s powerful LC/MS solutions portfolio. A new LC/TQ will be introduced that incorporates numerous intelligence features oriented towards demanding routine analysis applications—also, a next-generation LC/Q-TOF featuring new instrument architecture also coupled with intelligence to maximize productivity.The new Agilent 1260 Infinity II Hybrid Multisampler will be on show, an HPLC autosampler that offers classical Flow-through and Agilent Feed Injection modes. For example, food LC/MS analysis sample preparation often requires a strong solvent, which can be challenging. The solvent effect can lead to sample breakthrough and poor peak shapes, especially when the injection volume increases. Agilent Feed Injection mode is a unique technology that mediates a strong sample solvent effect by infusing the sample continuously into the mobile phase stream, improving peak shapes and sensitivity.New Agilent MassHunter Software Suite highlights include the Agilent AI Peak Integration Software for MassHunter Quant, which replaces manual peak integration with adaptable AI-assisted peak detection and integration. Analytical test labs using GC/MS Single Quadrupole will benefit from deep learning and continuous learning feedback that improves model performance over time, particularly for rare compound detection.Story continuesAlso, Agilent’s MassHunter BioConfirm 12.1 Software enables the interpretation of ECD fragmentation and enhancements to strengthen the peptide mapping workflow. BioConfirm 12.1 continues to offer powerful biopharma workflows for our customers with the highest quality oligonucleotide data, extracting information to assess impurities, confirm intact protein molecular weights, peptide sequence coverage, and the location of post-translational modifications, and the identification of released glycans."These new products demonstrate how intelligence features continue to improve analytical performance and lab productivity, automating difficult and challenging tasks, making mass spectrometry more accessible to all researchers," said Ken Suzuki, vice president and general manager of Agilent’s Mass Spectrometry Division.Agilent will hold several events at ASMS 2023. Agilent will host its annual Ion Mobility User Meeting on Sunday, June 4, from 2:00 – 5:00 p.m. at the Marriott Marquis Hotel in Houston. Agilent will also host breakfast sessions Monday, June 5 – Wednesday, June 7, from 7:00 – 8:15 a.m. in the George R. Brown Convention Center and the Agilent Hospitality Suite. Additional information on these and other events is available at Agilent at ASMS.ASMS attendees are invited to visit Agilent's Exhibition Booth #600 at the George R. Brown Convention Center and to spend time at the Agilent Hospitality Suite at the Hilton Americas Houston, Ballroom EF, Monday, June 5 – Wednesday, June 7 from 8:00 – 10:30 p.m. Agilent is a corporate member of ASMS and multi-year co-sponsor of the annual event.Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230602005072/en/ContactsMEDIA CONTACT Naomi GoumilloutAgilent Technologies Inc.+1.781.266.2819naomi.goumillout@agilent.com | Business Wire | "2023-06-02T12:00:00" | Agilent Intelligent Mass Spectrometry Solutions to Inspire at ASMS 2023 | https://finance.yahoo.com/news/agilent-intelligent-mass-spectrometry-solutions-120000872.html | f22de1f1-e6b3-3a5f-8e31-3c430007cbad |
A | Streamlined analysis of 40 PFAS compounds in wastewater and soilSANTA CLARA, Calif., June 05, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today a highly-anticipated, complete workflow solution for targeted per- and polyfluoroalkyl substances (PFAS) analysis using the United States (US) Environmental Protection Agency (EPA) Method 1633 (3rd draft). EPA Draft Method 1633 currently analyzes 40 PFAS compounds in wastewater and soil and is a complex and labor-intensive method, relying on multiple sample preparation and analysis steps. Success in running the technique depends on careful sample handling and the appropriate sample preparation supplies and instrumentation.The new workflow synchronizes with the recent launch of the Agilent 6495 Triple Quadrupole LC/MS (LC/TQ) system along with specific PFAS consumables, including the Agilent Bond Elut PFAS WAX Solid Phase Extraction (SPE) Cartridges, that provide the best recoveries while eliminating PFAS contamination and background, as well as the Agilent Infinity Lab PFC-free HPLC conversion kit, ‘PFAS-free’ Agilent vials and caps and other consumables. Specific data reporting needs for EPA 1633 are addressed through Agilent’s MassHunter Software, and sample tracking of the entire workflow can be done using the Agilent SLIMS Lab Management Platform enabling automation in data review and sample tracking which increases efficiency."PFAS are persistent, bioaccumulative, and of concern globally, with several countries looking to regulate them in water and soil. As a market leader in environmental analysis, Agilent is pleased to offer our customers a solution to achieve EPA Method 1633 performance requirements confidently," explained Ken Suzuki, vice president and general manager of Agilent’s Mass Spectrometry Division. "This new workflow simplifies setup and provides a robust end-to-end analytical methodology that reduces method development time, increases throughput and accuracy, allowing customers to focus on running critical samples."Story continuesAgilent’s Bond Elut PFAS WAX SPE Cartridges are explicitly designed for PFAS analysis, providing excellent extraction performance and flow rates for a broad range of PFAS compounds while complying with stringent regulatory requirements. The cartridges undergo PFAS-specific QC testing to ensure optimal cleanliness and recovery, so customers can confidently isolate PFAS from environmental matrices, such as wastewater and soil.SLIMS simplifies the intake of analytical requests and streamlines task management. Connected to the 6495 LC/TQ SLIMS guides users through the workflow and ensures the instrument, consumables, and reagents are fit for purpose. MassHunter software generates specific instrument data reports passing the information to SLIMS for evaluation of results and creation of the certificate of analysis.About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230605005280/en/ContactsMEDIA CONTACT Naomi GoumilloutAgilent Technologies, Inc.+1.781.266.2819naomi.goumillout@agilent.com | Business Wire | "2023-06-05T12:00:00" | Agilent Announces Full Workflow for US EPA Method 1633 for Targeted PFAS Analysis | https://finance.yahoo.com/news/agilent-announces-full-workflow-us-120000701.html | cfa3faa4-e0b9-3c53-b1d7-ee6b878fade0 |
A | SANTA CLARA, Calif., June 05, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced two new liquid chromatography mass spectrometry systems (LCMS), the Agilent 6495D LC/TQ and the Agilent Revident LC/Q-TOF. Facilitating the high-end performance of the Revident LC/Q-TOF, Agilent is also announcing the new Agilent MassHunter Explorer Profiling software and the new Agilent ChemVista library manager software.The superior Agilent 6495 Triple Quadrupole LC/MS (LC/TQ) System is ideal for demanding and challenging targeted analysis applications requiring the highest analytical sensitivity. The 6495 LC/TQ incorporates numerous intelligence features that address the critical transition between the ‘discovery phase’ of research and the ‘translational phase’ where studying a large volume of samples is crucial for generating meaningful scientific insights. The 6495 LC/TQ instrument was built for research with production-ready robustness, ensuring increased sample measurements due to greater efficiency and reduced instrument downtime. Intelligence features also include sub-millisecond dwell times and Intelligent Reflex that provides fast, sensitive, high-quality data, while early maintenance feedback and scheduled tuning keep the LC/TQ in peak working condition.The Agilent Revident Quadrupole Time-of-Flight LC/MS (LC/QTOF) System offers an entirely new instrument architecture coupled with instrument intelligence for maximized operation time and productivity. Revident is targeted toward food safety and environmental analysis but also has applications in other small molecule markets, from metabolomics to pharmaceuticals. Incorporating the new MassHunter Explorer Software, untargeted analyses are simplified by allowing data exploration, including statistical analysis and identification in a single software. Tasks can be performed faster with fewer errors and less expertise without compromising quality or accuracy. Additionally, the new ChemVista library manager software integrates extensive curated libraries. It enables third-party import and export into a tool that conveniently connects to MassHunter, allowing access to vast external databases for identification workflows.Story continues"The new 6495D LC/TQ offers significant improvements in sensitivity and speed over the current 6495C, which is already a reputable high-end LC/TQ, while the Revident LC/Q-TOF is the first of a new generation of LC/Q-TOF systems," said Sudharshana Seshadri, vice president and general manager of Agilent’s Liquid Chromatography, Mass Spectrometry, and Automation Divisions."This launch expands the instrument intelligence from our TQ product line to our Q-TOF. Revident also includes a novel detection system that greatly enhances spectral purity, and combined with our new MassHunter Explorer Profiling and ChemVista library manager software, the Revident LC/Q-TOF is revolutionizing our customers’ experience with LC/Q-TOF—providing the highest, yet relevant, performance for meaningful scientific insights," Seshadri added.Agilent is a leading solution provider of proven, robust, and reliable mass spectrometry technologies to a range of segments and a wide array of applications in the bio/pharma, life science research, food, and environmental markets. These new technological capabilities enable Agilent’s customers to increase data quality and interpretation while reducing the time and human attention required—more easily adapting to ever-changing market needs.About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230605005279/en/ContactsMEDIA CONTACTNaomi GoumilloutAgilent Technologies, Inc.+1.781.266.2819naomi.goumillout@agilent.com | Business Wire | "2023-06-05T12:00:00" | Agilent Announces Inspirational LC/TQ and LC/Q-TOF Mass Spectrometry Solutions at ASMS 2023 | https://finance.yahoo.com/news/agilent-announces-inspirational-lc-tq-120000928.html | ce10e349-390e-3f53-aa6d-338dda3991cb |
A | SANTA CLARA, Calif., June 06, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of the enhanced xCELLigence RTCA Software Pro Version 2.8, an integrated software package for running and analyzing real-time cell analysis data. This improved version enables Agilent xCELLigence Real-Time Cell Analysis (RTCA) systems in GMP-regulated facilities.The xCELLigence RTCA Software Pro enables data integrity controls to support regulatory requirements defined in FDA 21 CFR Part 11 and EU GMP Annex 11 for electronic records and electronic signatures, an essential requirement in pharmaceutical and biopharmaceutical manufacturing. New and enhanced features ensure that data and electronic records generated with xCELLigence RTCA systems are trustworthy, authentic, and reliable and meet GMP manufacturing compliance requirements.The xCELLigence RTCA system provides an essential functional potency assay in cell therapy development, manufacturing, and safety applications. Agilent instrumentation and software, alongside customer user organization controls, enables customers to meet FDA 21 CFR Part 11 and other applicable regulatory requirements. This system empowers customers to meet the demands of cell therapy discovery, process development, and QC-release criteria."The addition of compliance features to xCELLigence RTCA Software Pro ensures that Agilent xCELLigence RTCA systems meet the regulatory needs of our valued customers, especially in manufacturing and quality control settings," said Todd Christian, vice president and general manager of Agilent’s Cell Analysis Division. "This bridges the regulatory gap, and reinforces Agilent as a leading cell analysis solutions provider to the pharma and biopharma industries."Agilent’s key focus is to support customers’ regulatory requirements through our instrumentation and software applications. These solutions for compliant environments support immuno-oncology and cell and gene therapy customers, who are developing key components to address human health concerns, furthering Agilent’s core mission to advance the quality of human life.Story continuesAbout Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230606005547/en/ContactsNaomi GoumilloutAgilent Technologies+1.781.266.2819naomi.goumillout@agilent.com | Business Wire | "2023-06-06T12:00:00" | Agilent Announces Enhanced xCELLigence RTCA Software Pro to Support Regulatory Compliance Requirements | https://finance.yahoo.com/news/agilent-announces-enhanced-xcelligence-rtca-120000457.html | 7a48f48f-e900-3623-a74b-911650b99cc6 |
A | Let's talk about the popular Agilent Technologies, Inc. (NYSE:A). The company's shares received a lot of attention from a substantial price movement on the NYSE over the last few months, increasing to US$144 at one point, and dropping to the lows of US$116. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Agilent Technologies' current trading price of US$118 reflective of the actual value of the large-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Agilent Technologies’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change. Check out our latest analysis for Agilent Technologies What Is Agilent Technologies Worth?The stock seems fairly valued at the moment according to my valuation model. It’s trading around 11.85% above my intrinsic value, which means if you buy Agilent Technologies today, you’d be paying a relatively reasonable price for it. And if you believe that the stock is really worth $105.81, there’s only an insignificant downside when the price falls to its real value. Is there another opportunity to buy low in the future? Since Agilent Technologies’s share price is quite volatile, we could potentially see it sink lower (or rise higher) in the future, giving us another chance to buy. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.What does the future of Agilent Technologies look like?earnings-and-revenue-growthFuture outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. With profit expected to grow by 27% over the next couple of years, the future seems bright for Agilent Technologies. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.Story continuesWhat This Means For YouAre you a shareholder? A’s optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at the stock? Will you have enough conviction to buy should the price fluctuates below the true value?Are you a potential investor? If you’ve been keeping tabs on A, now may not be the most optimal time to buy, given it is trading around its fair value. However, the optimistic prospect is encouraging for the company, which means it’s worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.Since timing is quite important when it comes to individual stock picking, it's worth taking a look at what those latest analysts forecasts are. At Simply Wall St, we have the analysts estimates which you can view by clicking here.If you are no longer interested in Agilent Technologies, you can use our free platform to see our list of over 50 other stocks with a high growth potential.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.Join A Paid User Research SessionYou’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here | Simply Wall St. | "2023-06-06T19:46:55" | Why Agilent Technologies, Inc. (NYSE:A) Could Be Worth Watching | https://finance.yahoo.com/news/why-agilent-technologies-inc-nyse-194655791.html | 79efbb54-5a0e-3974-a08c-e8249e3ac110 |
A | Agilent Technologies A expanded its liquid chromatography mass spectrometry (LCMS) offerings with the launch of the 6495 Triple Quadrupole LC/MS (LC/TQ) System and the Revident Quadrupole Time-of-Flight LC/MS (LC/QTOF) System.Notably, 6495 LC/TQ is designed to take care of the critical transition between the discovery phase of research and the translational phase to generate meaningful scientific insights on the back of its intelligence features.Thus, Agilent is likely to gain momentum among the targeted analysis applications that require the highest analytical sensitivity.Meanwhile, Revident LC/Q-TOF features instrument intelligence for maximized operation time and productivity and a novel detection system that boosts spectral purity.In addition to the new LCMS systems, Agilent unveiled MassHunter Explorer Profiling software and the new ChemVista library manager software, both of which are integrated with Revident LC/Q-TOF for delivering meaningful scientific insights.With Revident LC/Q-TO, the company is set to gain traction across food safety and environmental analysis and applications in other small molecule markets.Agilent Technologies, Inc. Price and ConsensusAgilent Technologies, Inc. Price and ConsensusAgilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. QuoteLSAG Segment in FocusThe latest move bodes well for the company’s growing efforts toward bolstering its Life Sciences & Applied Markets Group (LSAG) segment, which contributes the most to total revenues.In second-quarter fiscal 2023, the segment generated $968 million in revenues, which accounted for 56% of the total revenues. The figure was up 8% on a reported basis and 10% on a core basis from the prior-year fiscal quarter’s levels.We believe the company’s strong focus on bolstering the LSAG segment is expected to contribute well to its overall performance, which in turn is likely to aid it in winning investors’ confidence in the days ahead.For fiscal 2023, Agilent expects revenues between $6.93 billion and $7.03 billion, implying growth of 1.2-2.7% on a reported basis and 3-4.5% on a core basis from the respective fiscal 2022 figures. The Zacks Consensus Estimate for Agilent's 2023 revenues is pegged at $6.99 billion, indicating growth of 2.1% from 2022.Coming to the price performance, Agilent has lost 21.4% in the year-to-date period against the industry’s growth of 2.3%.Story continuesExpanding PortfolioApart from the latest LCMS systems, the company rolled out the Cary 3500 Flexible UV-Vis System to strengthen its OpenLab software suite. The new spectrophotometer is ideal for analyzing liquid samples and characterizing solid samples as it features a large sample compartment with a small footprint.Further, the company announced the acquisition of e-Msion, which is known for an innovative electron capture dissociation (ECD) technology called the ExD cell. As part of the deal, the ExD cell will be integrated into Agilent’s advanced workflows, instruments and analytical solutions, which in turn will drive Agilent’s momentum across laboratories as well as among biological researchers.Also, Agilent announced the acquisition of Avida Biomed, which develops high-performance target enrichment workflows to aid clinical researchers using next-generation sequencing (NGS) approaches in studying cancer.The solutions of Avida Biomed highly complement Agilent’s SureSelect portfolio and NGS offerings. It has added strength to A’s portfolio of clinical research solutions. The acquisition is expected to help Agilent strengthen its Diagnostics and Genomics Group (DGG) segment.We believe that the growing portfolio offerings will continue to help Agilent strengthen its presence across various end markets.Zacks Rank & Stocks to ConsiderCurrently, Agilent Technologies carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the broader technology sector are Palo Alto Networks PANW, NVIDIA NVDA and AMETEK AME. While Palo Alto Networks and NVIDIA sport a Zacks Rank #1 (Strong Buy), AME carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Palo Alto Networks shares have gained 61.9% in the year-to-date period. The long-term earnings growth rate for PANW is currently projected at 31.5%.NVIDIA shares have gained 166.1% in the year-to-date period. Its long-term earnings growth rate is presently projected at 23.02%.AMTEK shares have gained 7% in the year-to-date period. The long-term earnings growth rate for AME is currently projected at 8.95%.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportNVIDIA Corporation (NVDA) : Free Stock Analysis ReportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportAMETEK, Inc. (AME) : Free Stock Analysis ReportPalo Alto Networks, Inc. (PANW) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research | Zacks | "2023-06-07T16:16:00" | Agilent (A) Boosts LCMS Portfolio With New Systems Launch | https://finance.yahoo.com/news/agilent-boosts-lcms-portfolio-systems-161600811.html | cd3a7b73-4d2b-35d2-8871-e645cb84850b |
A | SANTA CLARA, Calif., June 08, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of the Agilent BioTek 406 FX washer dispenser, a compact instrument that combines multifunctional reagent dispensing and plate-washing capabilities. The BioTek 406 FX offers expanded liquid handling features designed for integration into automated systems and standalone benchtop use.Key features of the new BioTek 406 FX improve upon the benefits of the first-generation EL406 and include:Secondary peristaltic and dual syringe pumps.A touchscreen interface.Enhanced flexibility for automated workflows across a broad range of applications, such as cell-based and magnetic bead-based assays.The additional reagent dispense pumps enable up to six different reagents to be dispensed using the pump technology best suited to each step of the workflow. Combining multiple assay workflow step capabilities in a single instrument is expected to be particularly beneficial for laboratories confronting space and budgetary constraints. The 406 FX plate carrier can be accessed from the right or left side, making it ideally suited for integration into robotic systems.Caleb Foster, associate vice president of marketing for Agilent's Cell Analysis Division, discussed the impact of the release. "The launch of the 406 FX is an exciting step in the evolution of the Agilent BioTek liquid handling product line – one that incorporates years of customer feedback received from the EL406," he said. "This flexible platform replaces several instruments in one, with market-leading multifunctional capabilities.""It's a true workhorse instrument that can be used for cell-based assays, ELISA, and many other microplate-based workflows, and it brings the flexibility and reliability customers have come to expect from our products," Foster added.BioTek microplate washer dispensers are used widely throughout the life sciences industry. They are an integral part of a suite of automation-friendly Agilent solutions that aim to improve throughput and ease of use in complex end-to-end cell analysis workflows.Story continuesAbout Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230608005192/en/ContactsNaomi GoumilloutAgilent Technologies Inc.+1.978.314.1862naomi.goumillout@agilent.com | Business Wire | "2023-06-08T12:00:00" | Agilent Announces BioTek 406 FX Washer Dispenser for Technology-Driven Workflow Efficiency | https://finance.yahoo.com/news/agilent-announces-biotek-406-fx-120000698.html | 7e697787-2da4-3e44-b539-4e69ec1fcb06 |
A | Labs seek guidance in reducing their environmental footprint by increasing efficiency but overall convey optimism on sustainability effortsSANTA CLARA, Calif., June 08, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the results of an independent third-party global survey that will help the industry better understand analytical laboratories’ perceptions, aspirations, and challenges concerning implementing sustainability measures.Conducted on behalf of Agilent by the international market research firm Frost & Sullivan, the survey sought to understand how lab managers globally are thinking about sustainability and reducing the environmental impact of their labs and how vendors like Agilent can help by improving products and services to address their needs and current gaps.The survey took a two-phased approach with 100 qualitative phone interviews, followed by 500 online interviews with experienced lab personnel in Asia, Europe, the United Kingdom, and the United States across all the lab types and market segments Agilent serves. The primary functions of the labs surveyed were analytical services, methods development or validation, process control, monitoring or manufacturing, quality assurance or control, research, and clinical testing.The results indicated that a high percentage (82%) of labs surveyed have already adopted sustainability measures. The top three actions that labs are currently undertaking to reduce their environmental footprint are: reducing carbon and other greenhouse gas emissions (72%), reducing or optimizing water and energy consumption (68%), and improving waste management techniques (60%). Also, 85% of those surveyed expect their vendors to support them in reaching their sustainability goals, now and in the future, and 74% of labs stated that it would be an exclusion criterion for them to engage with a company commercially that did not have a commitment to net zero."A majority of labs stated that information shared by vendors, related to their own goals and objectives towards sustainability, in addition to instrument and product-related information, was important," said Neil Rees, head of Agilent’s ESG Programs. "Our ongoing partnership with My Green Lab and their ACT Environmental Impact Factor Label program ensures that we can offer our customers third-party verified information on the environmental impact of Agilent solutions."Story continues"By providing the necessary verification and transparency of sustainability information, MGL ACT labels help consumers make informed decisions across the lifecycle impact of laboratory products," said James Connelly, My Green Lab CEO. "Participating in ACT is a key way manufacturers demonstrate their commitment to our mission to build a global culture of sustainability in science."Additionally, 54% of labs would be interested in consulting services to assess and improve lab efficiency, followed by instruments and systems that support tracking and monitoring key metrics related to sustainability (44%). Labs are also looking to vendors to provide instrument end-of-life solutions, for example, recycling services (77%) and instrument refurbishment initiatives (51%), such as Agilent’s Certified Pre-Owned Instruments Program. Agilent also showcased a selection of its MGL ACT-labelled products at the ASMS Conference held June 4 - 8 in Houston, Texas."As our customers’ definition of sustainability expands, it’s incumbent on us to be ahead of the curve in understanding their needs," Rees added. "Independent surveys such as this provide clear and impartial feedback, identifying trends and gaps that we can action, to continue to provide solutions that help ensure our customers’ sustainability goals are met or exceeded.""It’s important that we share these results with the wider community as we are all on the journey to be more sustainable," said Victoria Wadsworth, associate vice president of Reputation Marketing at Agilent. "By sharing these learnings, we can spark richer conversations and share best practices that bring everyone closer to their goals. It’s the right thing to do for business and our planet."Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230608005204/en/ContactsNaomi GoumilloutAgilent Technologies, Inc.+1.781.266.2819naomi.goumillout@agilent.com | Business Wire | "2023-06-08T12:00:00" | Agilent Independent Global Lab Sustainability Survey Sheds Light on Progress Towards Greener Labs | https://finance.yahoo.com/news/agilent-independent-global-lab-sustainability-120000349.html | 64e43790-efd7-3076-ac75-c4e436dfd55a |
A | Integration of Polymer Standards Service Ltd. products results in the most complete and versatile GPC/SEC portfolio on the marketSANTA CLARA, Calif., June 12, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced they will showcase their significantly expanded InfinityLab GPC/SEC Solution at the HPLC 2023 conference on June 18 – 22, 2023 in Düsseldorf, Germany.The Agilent InfinityLab GPC/SEC portfolio has become even more comprehensive as it incorporates added value components from recent acquisition of Polymer Standard Service Ltd. (PSS) including a dedicated GPC/SEC Column Thermostat, a Multi-Angle Light Scattering Detector, the GPC/SEC-Ready Kit, and the powerful WinGPC Software into the already existing InfinityLab GPC/SEC Solutions for advanced material characterization.In combination with Agilent GPC/SEC products like the Bio-GPC/SEC system, High-Temperature GPC system, routine-GPC/SEC software, GPC/SEC columns, standards, and dedicated service offerings this launch of additional products results in the largest one-vendor solution for GPC/SEC."We are so pleased to unveil the new GPC/SEC solutions at HPLC," said Sudharshana Seshadri, vice president of Agilent’s Liquid Chromatography, Mass Spec and Automation divisions. "The combined portfolio of Agilent and PSS delivers a total Agilent solution for the characterization of macromolecules. It enables scientists to update legacy methods, to improve productivity or to address the challenges of characterizing new and innovative high-performance materials for applications within the food, pharmaceutical and biotechnology industries.""Our goal at Agilent," continued Sudharshana Seshadri, "is to deliver the best solutions we can for our customers, considering their current and future needs. Having PSS on board brings unique expertise in serving macromolecular analysis, and combining that with Agilent’s knowledge, and strengths, enables us to address the emerging challenges that customers are facing."Story continuesAlso on display, for the first time in Europe at the HPLC 2023 conference, on the Agilent booth #3 will be: 1260 Infinity II Hybrid Multisampler offering unique capabilities for complex samples; the 1290 Infinity II Bio Online Sample Manager which together with the 1290 Infinity II LC systems, creates a high-end PAT-solution, and the Revident Quadrupole Time-of-Flight LC/MS (LC/Q-TOF) System.Agilent’s second booth #4 will showcase Agilent’s digital lab solutions. Lab optimization strategies will be articulated around key solutions such as efficient data management systems, electronic laboratory notebooks, scientific asset performance management and digital tools designed to track inventories, manage schedules, aggregate data, provide resource visibility, monitor asset performance & utilization, and integrate with other lab systems.GPC/SECGel Permeation Chromatography / Size Exclusion Chromatography (GPC/SEC) is an important separation technique for synthetic and natural polymers. GPC/SEC analysis is widely used in the chemical-, food-, pharmaceutical- and biopharmaceutical industry and research in applications to determine the molecular weight and size distribution of macromolecules.About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230612005069/en/ContactsCatherine KayeAgilent Technologies+44 (0) 7775 410632Catherine.kaye@agilent.com | Business Wire | "2023-06-12T12:00:00" | Agilent Introduces New Comprehensive GPC/SEC Solutions at HPLC 2023 Conference | https://finance.yahoo.com/news/agilent-introduces-comprehensive-gpc-sec-120000312.html | e2e9e23d-c964-3280-979d-52f269bf8ffd |
A | Baron Funds, an investment management firm, released its "Baron Durable Advantage Fund" first quarter 2023 investor letter, a copy of which can be downloaded here. The Baron Durable Advantage Fund gained 16.0% during the first quarter, compared favorably to its S&P 500 benchmark which earned a 7.5% return for the same period. Spare some time to check the fund’s top 5 holdings to know more about their top bets for 2023.In its Q1 2023 investor letter, Baron Durable Advantage Fund mentioned Agilent Technologies Inc. (NYSE:A) and explained its insights for the company. Founded in 1999, Agilent Technologies Inc. (NYSE:A) is a Santa Clara, California-based research and testing company with a $35.2 billion market capitalization. Agilent Technologies Inc. (NYSE:A) delivered a -20.35% return since the beginning of the year, while its 12-month returns are up by 2.75%. The stock closed at $118.54 per share on June 12, 2023.Here is what Baron Durable Advantage Fund has to say about Agilent Technologies Inc. (NYSE:A) in its Q1 2023 investor letter:"Agilent Technologies, Inc. (A) provides instruments, software, services, and consumables for the life sciences, diagnostics, and applied chemicals markets. Despite reporting solid financial results with 10% year-over-year core revenue growth and 13% EPS growth, shares declined 7.6% during the first quarter on investor anticipation of a tougher macro environment later in 2023. We continue to believe Agilent is well positioned for long-term durable growth, driven by innovation, new product development, and its end market and geographic mix. Over time, Agilent will benefit from a shift in its business mix to higher-growth pharmaceutical, diagnostics, and research markets, while its leading competitive positioning and scale should enable it to raise margins over time."Our calculations show that Agilent Technologies Inc. (NYSE:A) was not able to secure a spot on our list of the 30 Most Popular Stocks Among Hedge Funds. Agilent Technologies Inc. (NYSE:A) was in 55 hedge fund portfolios at the end of the first quarter of 2023, compared to 48 funds in the previous quarter. Agilent Technologies Inc. (NYSE:A) delivered a -13.87% return in the past 3 months.Story continuesOn January this year, we also shared another hedge fund’s views on Agilent Technologies Inc. (NYSE:A) in another article. You can find other investor letters from hedge funds and prominent investors on our hedge fund investor letters Q1 2023 page. Suggested Articles:25 Countries With The Highest Cost of Living In The World in 202320 Best Countries to Retire Overseas Where English is Spoken12 Best Energy Stocks To Invest In According to AnalystsDisclosure: None. This article is originally published at Insider Monkey. | Insider Monkey | "2023-06-13T16:02:51" | Is it a Good Time to Invest in Agilent (A) Shares? | https://finance.yahoo.com/news/auto-draft-160255368.html | 60bfb7fa-9248-3d17-b654-6b18858a4e5c |
A | Agilent Technologies A is constantly gaining traction in molecular analyses on the back of its strength in liquid chromatography mass spectrometry (LCMS) offerings.This is evident from its latest InfinityLab Gel Permeation Chromatography/Size Exclusion Chromatography (GPC/SEC) solutions, which the company is gearing up to showcase at the HPLC 2023 conference.With the new solutions, which are designed for advanced material characterization, the company strengthened its Agilent InfinityLab GPC/SEC portfolio. Moreover, the portfolio now includes the benefits of the Polymer Standard Service acquisition.Notably, the new additions include the likes GPC/SEC column thermostat, the GPC/SEC-Ready Kit, a multi-angle light scattering detector and the powerful WinGPC Software.The combined portfolio of InfinityLab GPC/SEC and Polymer Standard Service will help Agilent cater well to the needs of scientists in macromolecular analysis.Also, it will aid its momentum across the chemical, food, pharmaceutical and biopharmaceutical industries.Agilent Technologies, Inc. Price and ConsensusAgilent Technologies, Inc. Price and ConsensusAgilent Technologies, Inc. price-consensus-chart | Agilent Technologies, Inc. QuoteLSAG Segment in FocusThe latest move bodes well for the company’s growing efforts toward bolstering its Life Sciences & Applied Markets Group (LSAG) segment, which contributes the most to total revenues.Apart from the expansion of the Agilent InfinityLab GPC/SEC portfolio, the company recently launched the 6495 Triple Quadrupole LC/MS (LC/TQ) System and the Revident Quadrupole Time-of-Flight LC/MS (LC/QTOF) System.Notably, 6495 LC/TQ is designed to take care of the critical transition between the discovery phase of research and the translational phase to generate meaningful scientific insights on the back of its intelligence features.Meanwhile, Revident LC/Q-TOF features instrument intelligence for maximized operation time and productivity and a novel detection system that boosts spectral purity.Story continuesTo ConcludeThe abovementioned endeavors are expected to continue aiding the performance of the LSAG segment.In second-quarter fiscal 2023, the underlined segment generated $968 million in revenues, which accounted for 56% of the total revenues. The figure was up 8% on a reported basis and 10% on a core basis from the prior-year fiscal quarter’s levels.We believe the company’s strong focus on bolstering the LSAG segment will benefit its overall performance.For fiscal 2023, Agilent expects revenues between $6.93 billion and $7.03 billion, implying growth of 1.2-2.7% on a reported basis and 3-4.5% on a core basis from the respective fiscal 2022 figures. The Zacks Consensus Estimate for Agilent's fiscal 2023 revenues is pegged at $6.99 billion, indicating growth of 2% from 2022.However, mounting expenses do not bode well for the company’s profitability. Further, macroeconomic headwinds and uncertainties in the demand environment remain concerns.Coming to price performance, Agilent has lost 20% in the year-to-date period against the industry’s growth of 4.5%.Zacks Rank & Stocks to ConsiderCurrently, Agilent Technologies carries a Zacks Rank #4 (Sell).Some better-ranked stocks in the broader technology sector are Palo Alto Networks PANW, NVIDIA NVDA and AMETEK AME. While Palo Alto Networks and NVIDIA sport a Zacks Rank #1 (Strong Buy) each, AME carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Palo Alto Networks shares have gained 65% in the year-to-date period. The long-term earnings growth rate for PANW is currently projected at 31.5%.NVIDIA shares rallied 173.8% in the year-to-date period. Its long-term earnings growth rate is presently projected at 23.02%.AMETEK shares have increased by 10.2% in the year-to-date period. The long-term earnings growth rate for AME is currently projected at 8.95%.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportNVIDIA Corporation (NVDA) : Free Stock Analysis ReportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportAMETEK, Inc. (AME) : Free Stock Analysis ReportPalo Alto Networks, Inc. (PANW) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research | Zacks | "2023-06-14T15:54:00" | Agilent (A) Boosts LSAG Segment With New GPC/SEC Solutions | https://finance.yahoo.com/news/agilent-boosts-lsag-segment-gpc-155400344.html | 12e219cf-9283-33d7-a609-0a826aba7397 |
A | Life-science stocks have struggled this year, with the iShares Biotechnology ETF suffering a negative return of 0.64%. The stocks' struggles have put them on average at a discount to Morningstar's fair-value estimate for the first time in five years.Continue reading | TheStreet.com | "2023-06-22T12:00:00" | Life Sciences Has Lagged; Morningstar Likes These Biotech Stocks | https://finance.yahoo.com/m/904e73a0-7b9d-3620-bd7c-1465c00df4ac/life-sciences-has-lagged-.html | 904e73a0-7b9d-3620-bd7c-1465c00df4ac |
A | A month has gone by since the last earnings report for Agilent Technologies (A). Shares have lost about 2.2% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Agilent due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.Agilent Q2 Earnings Match EstimatesAgilent Technologies reported second-quarter fiscal 2023 earnings of $1.27 per share, which came in line with the Zacks Consensus Estimate. The bottom line increased by 12.4% from the year-ago fiscal quarter’s level.Revenues of $1.72 billion surpassed the Zacks Consensus Estimate of $1.67 billion. The top line was up 6.8% on a reported basis and 9.5% on a core basis from the respective year-ago fiscal quarter’s levels.Top-line growth was driven by strong momentum across Food, Academia & Gov’t and Chemistry & Advanced Materials markets. A strong performance in China also contributed well.Segmental Top Line DetailsAgilent has three reporting segments, namely, Life Sciences & Applied Markets Group (LSAG), Agilent Cross Lab Group (ACG) and Diagnostics and Genomics Group (DGG).LSAG: The segment accounted for $968 million or 56% of its total revenues, up 8% on a reported basis and 10% on a core basis from the respective prior-year fiscal quarter’s levels. This was driven by strong performance in the Chemical & Advanced Materials, Food and Academic & Gov’t markets. Strength in LC and LCMS and lab consumables also aided results.ACG: Revenues from the segment were $387 million, accounting for 23% of total revenues. Also, the top line improved by 10% from the prior-year fiscal quarter’s reading on a reported basis and 13% on a core basis, driven by strength in services attached to new instrument installations as well as expanding service offerings for the existing instrument base.DGG: Revenues increased 1% from the prior-year fiscal quarter’s figure on a reported basis and 3% on a core basis to $362 million, accounting for the remaining 21% of total revenues. Segmental growth was attributed to strength in the NASD and pathology businesses. Also, solid momentum in companion diagnostics pharma services contributed well.Story continuesOperating ResultsFor the fiscal second quarter, gross margin in the LSAG segment expanded by 90 basis points (bps) to 59.9% from the prior-year fiscal quarter’s number. ACG’s gross margin contracted 10 bps to 47%. DGG’s gross margin contracted 420 bps from the year-ago fiscal quarter’s actuals to 51.8%.Research & development (R&D) costs were $126 million, up 9.6% from the prior-year fiscal quarter’s number. Selling, general & administrative (SG&A) expenses were $415 million, up 7.5% from the year-earlier fiscal quarter’s figure. As a percentage of revenues, R&D expenses expanded 10 bps year over year to 7.3%. Meanwhile, SG&A expenses expanded 20 bps year over year to 24.2%.Operating margin for the fiscal first quarter was 22.3%, which contracted 10 bps from the year-earlier fiscal quarter’s figure.Segment-wise, the operating margin for LSAG was up 180 bps from the year-earlier fiscal quarter’s level of 27.3%. ACG’s operating margin was 26.6%, up 200 bps from the year-ago fiscal quarter’s level. DGG segment’s operating margin contracted 530 bps to 20.2% from the year-ago fiscal quarter’s figure.Balance Sheet & Cash FlowAs of Apr 30, 2023, Agilent’s cash and cash equivalents were $1.18 billion, down from $1.25 billion on Jan 31, 2023.Accounts receivables were $1.4 billion at the end of second-quarter fiscal 2023, down from $1.5 billion at the end of first-quarter fiscal 2023.Long-term debt was $2.733 billion for the reported quarter, which remained flat as compared with the prior fiscal quarter.Agilent generated $398 million in cash from operations during the reported quarter, up from $296 million generated in the previous quarter.Further, it returned $151 million to shareholders, out of which dividend payments accounted for $66 million and share repurchases accounted for the remaining $85 million.GuidanceFor the fiscal third quarter of 2023, management expects revenues of $1.640-$1.675 billion, suggesting growth between 4.5% and 2.5% on a core basis from the year-ago fiscal quarter’s actuals.Non-GAAP earnings per share are expected to be $1.36-$1.38.For fiscal 2023, management lowered its revenue guidance from the band of $7.03-$7.1 billion to $6.93-7.03 billion, implying a growth of 1.2-2.7% on a reported basis and 3-4.5% on a core basis from the respective fiscal 2022 figures.Management also updated the guidance for fiscal 2023 non-GAAP earnings per share downward from $5.65-$5.70 to $5.60-$5.65.How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in fresh estimates.VGM ScoresAt this time, Agilent has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Agilent has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research | Zacks | "2023-06-22T15:30:16" | Agilent (A) Down 2.2% Since Last Earnings Report: Can It Rebound? | https://finance.yahoo.com/news/agilent-down-2-2-since-153016196.html | ae802d93-e908-3b47-a275-408cfcb562c5 |
A | Agilent Technologies (A) closed at $119.42 in the latest trading session, marking a +0.62% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.77%. At the same time, the Dow lost 0.65%, and the tech-heavy Nasdaq lost 2.23%.Coming into today, shares of the scientific instrument maker had lost 0.68% in the past month. In that same time, the Computer and Technology sector gained 6.75%, while the S&P 500 gained 4.66%.Wall Street will be looking for positivity from Agilent Technologies as it approaches its next earnings report date. In that report, analysts expect Agilent Technologies to post earnings of $1.37 per share. This would mark year-over-year growth of 2.24%. Our most recent consensus estimate is calling for quarterly revenue of $1.66 billion, down 3.5% from the year-ago period.A's full-year Zacks Consensus Estimates are calling for earnings of $5.61 per share and revenue of $6.99 billion. These results would represent year-over-year changes of +7.47% and +2.04%, respectively.Investors should also note any recent changes to analyst estimates for Agilent Technologies. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.15% lower. Agilent Technologies is currently a Zacks Rank #4 (Sell).Looking at its valuation, Agilent Technologies is holding a Forward P/E ratio of 21.14. This valuation marks a discount compared to its industry's average Forward P/E of 25.53.Story continuesWe can also see that A currently has a PEG ratio of 1.92. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. A's industry had an average PEG ratio of 2.78 as of yesterday's close.The Electronics - Testing Equipment industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 61, which puts it in the top 25% of all 250+ industries.The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.To follow An in the coming trading sessions, be sure to utilize Zacks.com.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research | Zacks | "2023-06-23T22:15:19" | Agilent Technologies (A) Gains As Market Dips: What You Should Know | https://finance.yahoo.com/news/agilent-technologies-gains-market-dips-221519990.html | b2ec615e-21f8-3d9b-86e2-8a2ee0cfeea6 |
A | New capabilities offer simplicity and walkup usability for multimode detectionSANTA CLARA, Calif., July 10, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of new Gen6 software for all Agilent BioTek detection instruments. Featuring a broad range of prebuilt experiment templates for common applications, the new software provides automated optimization tools and improved navigation through built-in data analysis functions.Modern laboratories house an array of sophisticated analytical instruments controlled by equally sophisticated – and often formidably complex – software. Straightforward instrument control interfaces that quickly and reliably connect users to essential results can significantly increase the speed and ease with which scientific research efforts move forward.The design of the Agilent BioTek Gen6 software facilitates ‘walkup’ convenience for all users, regardless of experience level. The software also features an intuitive user interface that enables complete control of BioTek microplate readers for absorbance, fluorescence, and luminescence measurements in a variety of microplates for both endpoint and kinetic assays. Reading parameters, plate layout, and data analysis definition are easily established through a step-by-step process for both quantitative and qualitative assays. Additionally, well data and analysis results can be exported automatically or fully customized to suit data reporting requirements."The new Gen6 software for Agilent BioTek microplate readers delivers an improved user experience," said Caleb Foster, associate vice president of marketing for Agilent's Cell Analysis Division. "Agilent continues to develop innovative new plate readers to support our customers’ needs, driven by extensive user feedback. Gen6 is next-generation software providing new and seasoned users with the tools required for existing and future applications."Story continuesGen6 software is standard on all new Agilent BioTek microplate readers; existing users of Gen5 software can purchase an upgrade to Gen6.About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230710563471/en/ContactsMEDIA CONTACTNaomi GoumilloutAgilent Technologies+1.781.266.2819naomi.goumillout@agilent.com | Business Wire | "2023-07-10T12:01:00" | Agilent Announces Gen6 Software for BioTek Line of Microplate Readers | https://finance.yahoo.com/news/agilent-announces-gen6-software-biotek-120100341.html | bec42551-4f7d-3ef1-b8c5-dfac5d41451b |
A | Employees once again rate the company as a top workplaceSANTA CLARA, Calif., July 10, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the company has achieved certification as a Great Place to Work®. The recognition reflects Agilent's commitment to creating a positive work environment that fosters employee engagement, innovation, teamwork and professional growth.Agilent earned Great Place to Work certification in Australia, Austria, Belgium, Brazil, Canada, China, Denmark, Finland, France, Germany, Hong Kong, India, Ireland, Italy, Japan, Malaysia, Mexico, Netherlands, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, the United Kingdom, and the United States.The Great Place to Work certification is awarded to companies that meet the highest standards of organizational culture and employee satisfaction. It is based on a survey of Agilent’s workforce administered by the Great Place to Work Institute, which assesses employee satisfaction in key areas, from credibility and respect to fairness and camaraderie."We are thrilled to be certified as a Great Place to Work," said Mike McMullen, president and CEO of Agilent Technologies. "This achievement is a testament to the exceptional efforts of our 18,000 employees who contribute to our collaborative and welcoming workplace. At Agilent, we believe that a strong culture is essential to driving innovation and delivering superior solutions to our customers."Employees rated Agilent equal to or higher than the world’s Top 25 best workplaces on a variety of key areas, with 89 percent agreeing the company is a great place to work.The Great Place to Work certification adds to other workplace accolades Agilent has received this year, including U.S. News and World Report’s Best Companies for Work-Life Balance and Newsweek’s Greatest Workplaces. Learn more about Agilent’s culture, people and careers at careers.agilent.com.Story continuesAbout Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230707274953/en/ContactsMEDIA CONTACT: Sarah Litton+1 669 255 7696sarah.litton@agilent.com | Business Wire | "2023-07-10T14:52:00" | Agilent Achieves Great Place to Work® Certification | https://finance.yahoo.com/news/agilent-achieves-great-place-certification-145200273.html | 9f984233-a70a-3dd1-9168-5b05311228a4 |
A | Cognex Corporation (CGNX) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 28%. A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.13, delivering a surprise of 44.44%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Cognex Corporation , which belongs to the Zacks Electronics - Testing Equipment industry, posted revenues of $242.51 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 4.99%. This compares to year-ago revenues of $274.63 million. The company has topped consensus revenue estimates three times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Cognex Corporation shares have added about 8.3% since the beginning of the year versus the S&P 500's gain of 17.6%.What's Next for Cognex Corporation?While Cognex Corporation has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Story continuesAhead of this earnings release, the estimate revisions trend for Cognex Corporation: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.29 on $248.76 million in revenues for the coming quarter and $0.95 on $934.45 million in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Electronics - Testing Equipment is currently in the top 23% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.One other stock from the same industry, Agilent Technologies (A), is yet to report results for the quarter ended July 2023. The results are expected to be released on August 15.This scientific instrument maker is expected to post quarterly earnings of $1.37 per share in its upcoming report, which represents a year-over-year change of +2.2%. The consensus EPS estimate for the quarter has been revised 0.2% lower over the last 30 days to the current level.Agilent Technologies' revenues are expected to be $1.66 billion, down 3.6% from the year-ago quarter.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportCognex Corporation (CGNX) : Free Stock Analysis ReportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research | Zacks | "2023-08-03T11:25:15" | Cognex Corporation (CGNX) Beats Q2 Earnings and Revenue Estimates | https://finance.yahoo.com/news/cognex-corporation-cgnx-beats-q2-112515938.html | b015f3df-9c5c-30ea-bc1a-f1b841d1f79d |
A | Technical University of Berlin researcher recognized for his innovative work in bioprocess engineeringSANTA CLARA, Calif., August 03, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced that Dr. Peter Neubauer has been selected to receive a prestigious Agilent Thought Leader Award. As Chair of Bioprocess Engineering at the Technical University of Berlin, Dr. Neubauer leads innovative research to identify new methods for more efficient bioprocess development, including genetic, cultivation, and analytical tools, with a particular focus on industrial-scale applications.Automation and high throughput are important for the real-time determination of critical quality attributes (CQAs), thus optimizing biotechnological applications. To this end, substantial resources are being directed toward developing process analytical technology (PAT) – a mechanism for designing, analyzing, and controlling pharmaceutical manufacturing processes by monitoring parameters that impact quality – to ultimately minimize public health risks.Dr. Neubauer’s work orchestrates hardware, software, automation, mathematical models, and AI to discover optimal conditions for PAT end-to-end workflows. Integrating intelligent technologies and automation into PAT solutions is a key factor for moving the pharmaceutical industry toward optimized bioprocesses that improve safety and reduce hands-on intervention. The Agilent Thought Leader Award will support his ongoing research into understanding and optimizing bioprocesses for difficult-to-express proteins and the development of scale-up/scale-down strategies."We are truly grateful and excited that Agilent's award will open up the opportunity to incorporate two-dimensional liquid chromatography and mass spectrometry into our upcoming bioprocess laboratory. The use of such leading-edge instrumentation is a fundamental element in our journey towards achieving a higher level in automated bioprocess development," said Dr. Neubauer who established and heads the KIWI-biolab as an International Future Laboratory for AI for Intelligent Integrated Biolaboratories. "Given our recent progress in seamlessly orchestrating all devices required in the process, ranging from extensive analyte-specific sample preparation to the management of big data, we feel ready to conquer this next logical step of integration."Story continues"Agilent is pleased to grant this Thought Leader Award to Dr. Neubauer to support his scientific developments in the biopharma space," said Sudharshana Seshadri, vice president and general manager of Agilent’s Liquid Chromatography, Mass Spectrometry, and Automation Divisions, and executive sponsor of the award. "His important work will help the pharmaceutical industry optimize their bioprocesses and accelerate improved healthcare worldwide."The Agilent Thought Leader Award program promotes fundamental scientific advances by contributing financial support, products, and expertise to the research of influential thought leaders in the life sciences, diagnostics, and chemical analysis space. To learn more, visit the Agilent Thought Leader Award website.About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230803578963/en/ContactsMEDIA CONTACTNaomi GoumilloutAgilent Technologies+1.978.314.1862naomi.goumillout@agilent.com | Business Wire | "2023-08-03T12:00:00" | Agilent Announces Thought Leader Award to Peter Neubauer | https://finance.yahoo.com/news/agilent-announces-thought-leader-award-120000858.html | b63a32f6-fed1-3073-8709-daf31b435fc3 |
A | UCLA scientist recognized for research developing live cell analytical tools to advance bioprocess and biomanufacturing applicationsSANTA CLARA, Calif., August 09, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that Ajit Divakaruni, Ph.D., has received the Agilent 2023 Early Career Professor Award. Dr. Divakaruni is an Assistant Professor in the Department of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA).The 2023 award focused on contributions to developing live cell analytical tools to identify and measure novel critical quality attributes to advance biomanufacturing applications. Dr. Divakaruni’s interest in developing cell-based metabolic assays to guide CAR-T cell manufacturing and bioprocess development strongly aligns with Agilent’s increasing attention to developing solutions that support immunotherapies and other cell-based therapies.The Divakaruni lab focuses on how energy metabolism and metabolic flexibility – the ability to switch between sugar, amino acid, and fatty acid oxidation in response to biological cues – can control cell function and fate. This research aims to discover novel regulatory points of metabolism and develop mitochondrial proteins and pathways as therapeutic drug targets."I am honored and beyond grateful to have been selected as this year’s recipient of the Agilent Early Career Professor Award. It is a privilege to be recognized for our work in developing mitochondrial and metabolic assays to help guide early-stage drug development and inform cell-based therapeutics," said Dr. Divakaruni. "Real-time, microplate-based assays have been central to the resurgent interest in cellular metabolism, and these will continue to be at the forefront as we continue to learn even more about how mitochondria and metabolism can shape cell function.""Dr. Divakaruni’s innovative research is expanding the basic science of understanding how cell metabolism can be a driver of cell function and fate and has also made critical contributions to live cell measurement tools that elevate researchers in this field," said Chong Wing Yung, associate director of University Relations and External Research at Agilent. "We are proud to further engage with Dr. Divakaruni and support his future research endeavors, including analytical technologies for bioprocess and biomanufacturing applications."Story continuesDr. Divakaruni’s current work includes studying the crosstalk between metabolism and innate immunity and examining how adjusting the balance between sugar, fat, and amino acid oxidation can affect metabolic and neurological disease. The development and refinement of functional mitochondrial measurements are central to this work, and the Divakaruni lab emphasizes protocols and ‘roadmap’ manuscripts that may assist other researchers as they plan their experiments.Future directions of Dr. Divakaruni’s research include developing novel cell-based metabolic assays to guide CAR-T cell bioprocess development and biomanufacturing. As critical quality attributes for producing efficacious cell therapies are still poorly defined, his expertise in cell metabolism and cell analysis will play a key role in helping to define these standards.The Agilent Early Career Professor Award is an annual program that recognizes and supports promising research from professors who, early in their careers, show outstanding potential for future research in areas of importance to the communities Agilent serves. This award underscores Agilent's commitment to furthering research through the company's products and services, financial support, and collaborative engagement by Agilent scientists and engineers. Further information about the program is available at Agilent.com.About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230809371185/en/ContactsNaomi GoumilloutAgilent Technologies+1.978.314.1862naomi.goumillout@agilent.com | Business Wire | "2023-08-09T12:00:00" | Agilent 2023 Early Career Professor Award Presented to Ajit Divakaruni | https://finance.yahoo.com/news/agilent-2023-early-career-professor-120000771.html | cb3fb834-e666-3566-b8da-e48bc6339b60 |
A | Agilent Technologies (A) closed at $127.63 in the latest trading session, marking a -0.56% move from the prior day. This change was narrower than the S&P 500's daily loss of 0.7%. Meanwhile, the Dow lost 0.54%, and the Nasdaq, a tech-heavy index, lost 1.17%.Coming into today, shares of the scientific instrument maker had gained 8.33% in the past month. In that same time, the Computer and Technology sector gained 1.4%, while the S&P 500 gained 2.35%.Investors will be hoping for strength from Agilent Technologies as it approaches its next earnings release, which is expected to be August 15, 2023. The company is expected to report EPS of $1.37, up 2.24% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $1.66 billion, down 3.56% from the prior-year quarter.For the full year, our Zacks Consensus Estimates are projecting earnings of $5.61 per share and revenue of $6.99 billion, which would represent changes of +7.47% and +2.07%, respectively, from the prior year.It is also important to note the recent changes to analyst estimates for Agilent Technologies. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.05% lower within the past month. Agilent Technologies is currently a Zacks Rank #3 (Hold).Digging into valuation, Agilent Technologies currently has a Forward P/E ratio of 22.87. This represents a discount compared to its industry's average Forward P/E of 25.76.Story continuesIt is also worth noting that A currently has a PEG ratio of 2.08. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Electronics - Testing Equipment stocks are, on average, holding a PEG ratio of 2.87 based on yesterday's closing prices.The Electronics - Testing Equipment industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 50, which puts it in the top 20% of all 250+ industries.The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportAgilent Technologies, Inc. (A) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research | Zacks | "2023-08-09T22:15:15" | Agilent Technologies (A) Stock Moves -0.56%: What You Should Know | https://finance.yahoo.com/news/agilent-technologies-stock-moves-0-221515546.html | 3af58521-aa5a-3ac4-8af8-4dd77e9ef858 |
A | Revenue at the high end of guidance and EPS exceeds guidanceFourth-quarter fiscal year 2023Revenue of $1.69 billion, down 8.7% reported and 9.7% core(1) from the fourth quarter of 2022.GAAP net income of $475 million; earnings per share (EPS) of $1.62, up 32% from the fourth quarter of 2022.Non-GAAP(2) net income of $404 million; EPS of $1.38, down 10% from the fourth quarter of 2022.Full fiscal year 2023Revenue of $6.83 billion, flat on a reported basis and up 1.5% core(1) year-over-year.GAAP net income of $1.240 billion; EPS of $4.19, flat year-over-year.Non-GAAP(2) net income of $1.609 billion; EPS of $5.44, up 4% year-over-year.Fiscal year 2024 and first-quarter outlookFiscal year 2024 revenue is expected in the range of $6.71 billion to $6.81 billion, representing a range of down 1.8% to 0.3% on a reported basis and down 0.5% to up 1% core(1). Fiscal year 2024 non-GAAP(3) earnings guidance is expected in the range of $5.44 to $5.55 per share.Fiscal first-quarter revenue guidance is expected in the range of $1.555 billion to $1.605 billion, a decline of 11.4% to 8.6% reported and a decline of 11.3% to 8.5% core(1). Fiscal first-quarter non-GAAP(3) earnings guidance is expected in the range of $1.20 to $1.23 per share.SANTA CLARA, Calif., November 20, 2023--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.69 billion for the fourth quarter ended Oct. 31, 2023, a decline of 8.7% reported and 9.7% core(1) compared to the fourth quarter of 2022.Fourth-quarter GAAP net income was $475 million, or $1.62 per share. This compares with $368 million, or $1.23 per share, in the fourth quarter of fiscal year 2022. Non-GAAP(2) net income was $404 million, or $1.38 per share during the quarter, compared with $456 million or $1.53 per share during the fourth quarter a year ago."The Agilent team continued its strong execution in Q4 and delivered leveraged earnings in 2023 during a challenging year for the industry," said President and CEO Mike McMullen. "As we look ahead to 2024, we anticipate a slow but steady recovery. We have high confidence in the markets in which we have invested, the strength and resilience of our team, and the benefits of our build and buy growth strategy. Agilent is well-positioned for long-term growth."Story continuesFinancial HighlightsLife Sciences and Applied Markets GroupAgilent’s Life Sciences and Applied Markets Group (LSAG) reported fourth-quarter revenue of $928 million, a decline of 17% reported and 18% core(1) year-over-year. LSAG’s operating margin for the quarter was 28.1%. Full-year revenue of $3.86 billion declined 4% reported and 2% core(1) over last year. LSAG’s operating margin for the year was 28.9%.Agilent CrossLab GroupThe Agilent CrossLab Group (ACG) reported fourth-quarter revenue of $404 million, an increase of 6% reported and 4% core(1) year-over-year. ACG’s operating margin for the quarter was 31.7%. Full-year revenue of $1.57 billion grew 8% reported and 10% core(1) over last year. ACG’s operating margin for the year was 29.5%.Diagnostics and Genomics GroupThe Diagnostics and Genomics Group (DGG) reported fourth-quarter revenue of $356 million, an increase of 1% reported and flat on a core(1) basis year-over-year. DGG’s operating margin for the quarter was 22.5%. Full-year revenue of $1.41 billion increased 1% reported and 3% core(1) year over year. DGG’s operating margin for the year was 21.0%.Full Year 2024 and First-Quarter OutlookFull-year revenue is expected to be in the range of $6.71 billion to $6.81 billion, a decline of 1.8% to 0.3% on a reported basis and down 0.5% to up 1% core(1). Full-year non-GAAP(3) EPS is expected to be in the range of $5.44 to $5.55 per share.The outlook for first-quarter revenue is expected to be in the range of $1.555 billion to $1.605 billion, a decline of 11.4% to 8.6% reported and a decline of 11.3% to 8.5% core(1). First-quarter non-GAAP(3) earnings guidance is expected to be in the range of $1.20 to $1.23 per share.The outlook is based on forecasted currency exchange rates.Conference CallAgilent’s management will present additional details regarding the company’s fourth-quarter 2023 financial results on a conference call with investors today at 1:30 p.m. PST. This event will be broadcast live online in listen-only mode. To listen to the webcast, select the "Q4 2023 Agilent Technologies Inc. Earnings Conference Call" link on the Agilent Investor Relations website. The webcast will remain on the company site for 90 days.About Agilent TechnologiesAgilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.Forward-Looking StatementsThis news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding Agilent’s growth prospects, business, financial results, revenue, and non-GAAP earnings guidance for Q1 and fiscal year 2024 and future amortization of intangibles. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of Agilent’s customers’ businesses; unforeseen changes in the demand for current and new products, technologies, and services; unforeseen changes in the currency markets; customer purchasing decisions and timing; and the risk that Agilent is not able to realize the savings expected from integration and restructuring activities. In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that its cost-cutting initiatives will impair its ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on its operations, its markets and its ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability of its supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; and other risks detailed in Agilent’s filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q for the fiscal quarter ended July 31, 2023. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.(1) Core revenue growth excludes the impact of currency and acquisitions and divestitures within the past 12 months. Core revenue is a non-GAAP measure. Reconciliations between GAAP revenue and core revenue for Q4 fiscal year 2023 and full fiscal year 2023 are set forth on pages 6 and 7 of the attached tables along with additional information regarding the use of this non-GAAP measure. Core revenue growth rate as projected for full fiscal year 2024 excludes the impact of currency and acquisitions and divestitures within the past 12 months. Most of the excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy and could differ materially. Therefore, no reconciliation to GAAP amounts has been provided for the projection.(2) Non-GAAP net income and non-GAAP earnings per share primarily exclude the impacts of restructuring and other related costs, asset impairments, intangibles amortization, transformational initiatives, acquisition and integration costs, business exit and divestiture costs, net loss on equity securities, pension settlement loss, special compliance costs, change in fair value of contingent consideration and loss on extinguishment of debt. Agilent also excludes any tax benefits or expenses that are not directly related to ongoing operations, and which are either isolated or are not expected to occur again with any regularity or predictability. A reconciliation between non-GAAP net income and GAAP net income is set forth on page 4 of the attached tables along with additional information regarding the use of this non-GAAP measure.(3) Non-GAAP earnings per share as projected for full fiscal year 2024 exclude primarily the estimated impacts of non-cash intangibles amortization, transformational initiatives, and acquisition and integration costs. Agilent also excludes any tax benefits or expenses that are not directly related to ongoing operations, and which are either isolated or are not expected to occur again with any regularity or predictability. Most of these excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy and could differ materially. Therefore, no reconciliation to GAAP amounts has been provided. Future amortization of intangibles is expected to be approximately $25 million per quarter.AGILENT TECHNOLOGIES, INC.CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS(In millions, except per share amounts)(Unaudited)PRELIMINARYThree Months EndedYears EndedOctober 31,October 31,2023202220232022Net revenue$1,688$1,849$6,833$6,848Costs and expenses:Cost of products and services7738373,3683,126Research and development114119481467Selling, general and administrative3934221,6341,637Total costs and expenses1,2801,3785,4835,230Income from operations4084711,3501,618Interest income175519Interest expense(22)(23)(95)(84)Other income (expense), net17233(39)Income before taxes4204551,3391,504Provision for (benefit from) income taxes(55)8799250Net income$475$368$1,240$1,254Net income per share:Basic$1.63$1.24$4.22$4.19Diluted$1.62$1.23$4.19$4.18Weighted average shares used in computing net income per share:Basic292296294299Diluted293298296300The preliminary income statement is estimated based on our current information.Page 1AGILENT TECHNOLOGIES, INC.CONDENSED CONSOLIDATED BALANCE SHEET(In millions, except par value and share amounts)(Unaudited)PRELIMINARYOctober 31,October 31,20232022ASSETSCurrent assets:Cash and cash equivalents$1,590$1,053Accounts receivable, net1,2911,405Inventory1,0311,038Other current assets274282Total current assets4,1863,778Property, plant and equipment, net1,2701,100Goodwill3,9603,952Other intangible assets, net475821Long-term investments164195Other assets708686Total assets$10,763$10,532LIABILITIES AND EQUITYCurrent liabilities:Accounts payable$418$580Employee compensation and benefits371455Deferred revenue505461Short-term debt—36Other accrued liabilities309329Total current liabilities1,6031,861Long-term debt2,7352,733Retirement and post-retirement benefits10397Other long-term liabilities477536Total liabilities4,9185,227Total Equity:Stockholders' equity:Preferred stock; $0.01 par value; 125,000,000 shares authorized; none issued and outstanding at October 31, 2023 and October 31, 2022——Common stock; $0.01 par value, 2,000,000,000 shares authorized; 292,123,241 shares at October 31, 2023 and 295,259,092 shares at October 31, 2022, issued and outstanding33Additional paid-in-capital5,3875,325Retained earnings782324Accumulated other comprehensive loss(327)(347)Total stockholders' equity5,8455,305Total liabilities and stockholders' equity$10,763$10,532The preliminary balance sheet is estimated based on our current information.Page 2AGILENT TECHNOLOGIES, INC.CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS(In millions)(Unaudited)PRELIMINARYYears EndedOctober 31,October 31,20232022Cash flows from operating activities:Net income$1,240$1,254Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization271317Share-based compensation111125Deferred taxes(56)8Excess and obsolete inventory related charges4024Net loss on equity securities4167Asset impairment charges277—Change in fair value of contingent consideration1(25)Loss on extinguishment of debt—9Net gain on divestiture of business(43)—Other non-cash expense, net611Changes in assets and liabilities:Accounts receivable, net132(321)Inventory(33)(248)Accounts payable(171)121Employee compensation and benefits(91)(22)Other assets and liabilities47(8)Net cash provided by operating activities (a)1,7721,312Cash flows from investing activities:Payments to acquire property, plant and equipment(298)(291)Proceeds from sale of equity securities522Payments to acquire equity securities(8)(13)Proceeds from convertible note4—Payments in exchange for convertible note(12)(4)Proceeds from divestiture of business50—Payments to acquire businesses and intangible assets, net of cash acquired(51)(52)Net cash used in investing activities(310)(338)Cash flows from financing activities:Proceeds from issuance of common stock under employee stock plans6758Payment of taxes related to net share settlement of equity awards(54)(67)Payments for repurchase of common stock(575)(1,139)Payments of dividends(265)(250)Proceeds from issuance of long-term debt—600Repayments of long-term debt—(609)Net proceeds from (repayment of) short-term debt(35)35Payment for contingent consideration(68)—Net cash used in financing activities(930)(1,372)Effect of exchange rate movements5(36)Net increase (decrease) in cash, cash equivalents and restricted cash537(434)Cash, cash equivalents and restricted cash at beginning of period1,0561,490Cash, cash equivalents and restricted cash at end of period$1,593$1,056Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet:Cash and cash equivalents$1,590$1,053Restricted cash, included in other assets33Total cash, cash equivalents and restricted cash$1,593$1,056(a) Cash payments included in operating activities:Income tax paid, net of refunds received$199$279Interest payments, net of capitalized interest$89$85The preliminary cash flow is estimated based on our current information.Page 3AGILENT TECHNOLOGIES, INC.NON-GAAP NET INCOME AND DILUTED EPS RECONCILIATIONS(In millions, except per share amounts)(Unaudited)PRELIMINARYThree Months EndedYears EndedOctober 31,October 31,2023202220232022Net IncomeDiluted EPSNet IncomeDiluted EPSNet IncomeDiluted EPSNet IncomeDiluted EPSGAAP net income$475$1.62$368$1.23$1,240...$4.19$1,254$4.18Non-GAAP adjustments:Restructuring and other related costs460.16——460.16——Asset impairments————2770.94——Intangible amortization270.09420.141390.471910.64Transformational initiatives(6)(0.02)90.03250.08300.10Acquisition and integration costs40.0160.02160.05250.08Business exit and divestiture costs (gain)(43)(0.15)——(43)(0.15)70.02Net loss on equity securities270.0950.02420.14630.21Pension settlement loss40.0140.0140.0140.01Special compliance costs————90.03——Change in fair value of contingent consideration————1—(25)(0.08)Loss on extinguishment of debt——————90.03Other(11)(0.03)100.03110.04120.04Adjustment for taxes (a)(119)(0.40)120.05(158)(0.52)(5)(0.01)Non-GAAP net income$404$1.38$456$1.53$1,609$5.44$1,565$5.22(a) The adjustment for taxes excludes tax expense (benefits) that management believes are not directly related to on-going operations and which are either isolated, temporary or cannot be expected to occur again with any regularity or predictability such as the realized gain/loss due to sale of a business, windfall benefits on stock compensation, and the impact of R&D capitalization under section 174 of the Tax Cuts and Jobs Act of 2017. For the three months and year ended October 31, 2023, management used a non-GAAP effective tax rate of 13.75%. For the three months ended October 31, 2022, management used a non-GAAP effective tax rate of 14.12%. For the year ended October 31, 2022, management used a non-GAAP effective tax rate of 14.00%.We provide non-GAAP net income and non-GAAP net income per share amounts in order to provide meaningful supplemental information regarding our operational performance and our prospects for the future. These supplemental measures exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, business exit and divestiture costs, net loss on equity securities, pension settlement loss, special compliance costs, change in fair value of contingent consideration and loss on extinguishment of debt .Restructuring and other related costs include incremental expenses incurred in the period associated with restructuring programs, usually aimed at changes in business and/or cost structure. Such costs may include one-time termination benefits, facility-related costs and contract termination fees.Asset impairments include assets that have been written down to their fair value.Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers including costs to move manufacturing, small site consolidations, legal entity and other business reorganizations, insourcing or outsourcing of activities. Such costs may include move and relocation costs, one-time termination benefits and other one-time reorganization costs. Included in this category are also expenses associated with company programs to transform our product lifecycle management (PLM) system, human resources and financial systems.Acquisition and integration costs include all incremental expenses incurred to effect a business combination. Such acquisition costs may include advisory, legal, accounting, valuation, and other professional or consulting fees. Such integration costs may include expenses directly related to integration of business and facility operations, the transfer of assets and intellectual property, information technology systems and infrastructure and other employee-related costs.Business exit and divestiture costs (gain) include costs and gain associated with business divestitures.Net loss on equity securities relates to the realized and unrealized mark-to-market adjustments for our marketable and non-marketable equity securities.Pension settlement loss relates to the relief of the US Retirement Plan pension obligation due to increased lump sum payouts over a specified accounting threshold.Special compliance costs include costs associated with transforming our processes to implement new regulations such as environmental compliance costs related to a prior acquisition, NASD site costs and certain tax reporting requirements.Change in fair value of contingent consideration represents changes in the fair value estimate of acquisition-related contingent consideration.Loss on extinguishment of debt for the year ended October 31, 2022 relates to the net loss recorded on the redemption of the $600 million outstanding 3.875% 2023 senior notes due on July 15, 2023, called on April 4, 2022 and settled on May 4, 2022.Other includes acceleration of share-based compensation expense and certain legal costs and settlements in addition to other miscellaneous adjustments.Our management uses non-GAAP measures to evaluate the performance of our core businesses, to estimate future core performance and to compensate employees. Since management finds this measure to be useful, we believe that our investors benefit from seeing our results "through the eyes" of management in addition to seeing our GAAP results. This information facilitates our management’s internal comparisons to our historical operating results as well as to the operating results of our competitors.Our management recognizes that items such as amortization of intangibles can have a material impact on our cash flows and/or our net income. Our GAAP financial statements including our statement of cash flows portray those effects. Although we believe it is useful for investors to see core performance free of special items, investors should understand that the excluded items are actual expenses that may impact the cash available to us for other uses. To gain a complete picture of all effects on the company’s profit and loss from any and all events, management does (and investors should) rely upon the GAAP income statement. The non-GAAP numbers focus instead upon the core business of the company, which is only a subset, albeit a critical one, of the company’s performance.Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.The preliminary non-GAAP net income and diluted EPS reconciliation is estimated based on our current information.Page 4AGILENT TECHNOLOGIES, INC.SEGMENT INFORMATION(In millions, except where noted)(Unaudited)PRELIMINARYQuarter-over-QuarterLife Sciences and Applied Markets GroupQ4'23Q4'22Revenue$928$1,116Gross Margin, %59.6%60.6%Income from Operations$261$365Operating margin, %28.1%32.7%Diagnostics and Genomics GroupQ4'23Q4'22Revenue$356$352Gross Margin, %51.9%51.0%Income from Operations$80$69Operating margin, %22.5%19.5%Agilent CrossLab GroupQ4'23Q4'22Revenue$404$381Gross Margin, %50.4%48.6%Income from Operations$128$104Operating margin, %31.7%27.4%Year-over-YearLife Sciences and Applied Markets GroupFY23FY22Revenue$3,856$4,007Gross Margin, %60.2%60.2%Income from Operations$1,116$1,186Operating margin, %28.9%29.6%Diagnostics and Genomics GroupFY23FY22Revenue$1,409$1,389Gross Margin, %51.8%53.5%Income from Operations$296$301Operating margin, %21.0%21.7%Agilent CrossLab GroupFY23FY22Revenue$1,568$1,452Gross Margin, %49.3%47.6%Income from Operations$463$370Operating margin, %29.5%25.5%Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, business exit and divestiture costs, special compliance costs and change in fair value of contingent consideration.Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.The preliminary segment information is estimated based on our current information.Page 5AGILENT TECHNOLOGIES, INC.RECONCILIATIONS OF REVENUE BY SEGMENTEXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)(in millions)(Unaudited)PRELIMINARYYear-over-YearGAAPYear-over-YearGAAP Revenue by SegmentQ4'23Q4'22% ChangeLife Sciences and Applied Markets Group$928$1,116(17%)Diagnostics and Genomics Group3563521%Agilent CrossLab Group4043816%Agilent$1,688$1,849(9%)Non-GAAP(excluding Acquisitions & Divestitures)Year-over-Yearat Constant Currency (a)Non GAAP Revenue by SegmentQ4'23Q4'22Year-over-Year% ChangeYear-over-Year% ChangePercentage Point Impact from CurrencyCurrent QuarterCurrency Impact (b)Life Sciences and Applied Markets Group$928$1,116(17%)(18%)1 ppt$9Diagnostics and Genomics Group3563502%—2 ppts5Agilent CrossLab Group4043816%4%2 ppts6Agilent (Core)$1,688$1,847(9%)(10%)1 ppt$20We compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.(a) The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.(b) The dollar impact from the current quarter currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.The preliminary reconciliation of GAAP revenue adjusted for recent acquisitions and divestitures and impact of currency is estimated based on our current information.Page 6AGILENT TECHNOLOGIES, INC.RECONCILIATIONS OF REVENUE BY SEGMENTEXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)(in millions)(Unaudited)PRELIMINARYYear-over-YearGAAPYear-over-YearGAAP Revenue by SegmentFY23FY22% ChangeLife Sciences and Applied Markets Group$3,856$4,007(4%)Diagnostics and Genomics Group1,4091,3891%Agilent CrossLab Group1,5681,4528%Agilent$6,833$6,848—Non-GAAP(excluding Acquisitions & Divestitures)Year-over-Yearat Constant Currency (a)Non GAAP Revenue by SegmentFY23FY22Year-over-Year% ChangeYear-over-Year% ChangePercentage Point Impact from CurrencyCurrent Quarter Currency Impact (b)Life Sciences and Applied Markets Group$3,849$4,007(4%)(2%)-2 ppts$(73)Diagnostics and Genomics Group1,4091,3872%3%-1 ppt(18)Agilent CrossLab Group1,5681,4528%10%-2 ppts(31)Agilent (Core)$6,826$6,846—1%-1 ppt$(122)We compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.(a) The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.(b) The dollar impact from the current year currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.The preliminary reconciliation of GAAP revenue adjusted for recent acquisitions and divestitures and impact of currency is estimated based on our current information.Page 7View source version on businesswire.com: https://www.businesswire.com/news/home/20231120915570/en/ContactsInvestor Contact: Parmeet Ahuja+1 408-345-8948parmeet_ahuja@agilent.comMedia Contact: Tom Beermann+1 408-553-2914tom.beermann@agilent.com | Business Wire | "2023-11-20T21:05:00" | Agilent Reports Fourth-Quarter Fiscal Year 2023 Financial Results | https://finance.yahoo.com/news/agilent-reports-fourth-quarter-fiscal-210500253.html | f4e5a747-e8e5-3721-a5ae-981af0a7cfb5 |
A | Fourth-quarter revenue declined by 8.7% reported and 9.7% core year-over-year.GAAP EPS increased by 32% in Q4, while non-GAAP EPS decreased by 10% compared to the same period last year.Full fiscal year 2023 revenue remained flat, with a slight core increase of 1.5% year-over-year.Agilent's fiscal year 2024 outlook anticipates a slow recovery with revenue expected to range between $6.71 billion and $6.81 billion.Warning! GuruFocus has detected 6 Warning Sign with GBDC.On November 20, 2023, Agilent Technologies Inc (NYSE:A) released its 8-K filing, detailing the financial results for the fourth quarter and full fiscal year 2023. The company reported a fourth-quarter revenue of $1.69 billion, which represents an 8.7% decrease on a reported basis and a 9.7% decrease on a core basis from the fourth quarter of 2022. Despite the revenue decline, Agilent's GAAP net income rose to $475 million, with earnings per share (EPS) climbing to $1.62, a 32% increase from the previous year's quarter. However, non-GAAP net income saw a decrease, with EPS dropping by 10% to $1.38.Fiscal Year 2023 Performance OverviewFor the full fiscal year 2023, Agilent's revenue remained flat at $6.83 billion on a reported basis but showed a modest core increase of 1.5% year-over-year. The GAAP net income for the year was $1.240 billion, with EPS remaining steady at $4.19. The non-GAAP net income for the year was $1.609 billion, with a 4% increase in EPS to $5.44.Segment Performance and OutlookThe Life Sciences and Applied Markets Group (LSAG) experienced a significant revenue decline of 17% reported and 18% core year-over-year in Q4, with a full-year revenue decrease of 4% reported and 2% core. Conversely, the Agilent CrossLab Group (ACG) saw a 6% reported and 4% core increase in Q4 revenue, with an 8% reported and 10% core growth for the full year. The Diagnostics and Genomics Group (DGG) reported a slight 1% increase in revenue on a reported basis and remained flat on a core basis for both the quarter and the full year.Story continuesLooking ahead to fiscal year 2024, Agilent expects revenue to be in the range of $6.71 billion to $6.81 billion, which would represent a slight decline to a marginal increase on a reported basis and a core basis, respectively. The non-GAAP EPS is projected to be between $5.44 and $5.55. For the fiscal first quarter, revenue is anticipated to decline by 11.4% to 8.6% reported and 11.3% to 8.5% core, with non-GAAP earnings guidance expected to be in the range of $1.20 to $1.23 per share.Financial Statements HighlightsAgilent's balance sheet as of October 31, 2023, shows an increase in total assets to $10.763 billion, up from $10.532 billion the previous year. The company's cash and cash equivalents also rose to $1.590 billion, compared to $1.053 billion in 2022. The condensed consolidated statement of cash flows indicates a net cash provided by operating activities of $1.772 billion for the year ended October 31, 2023, a notable increase from $1.312 billion in the previous year.Management Commentary"The Agilent team continued its strong execution in Q4 and delivered leveraged earnings in 2023 during a challenging year for the industry," said President and CEO Mike McMullen. "As we look ahead to 2024, we anticipate a slow but steady recovery. We have high confidence in the markets in which we have invested, the strength and resilience of our team, and the benefits of our build and buy growth strategy. Agilent is well-positioned for long-term growth."Agilent's financial performance in the fourth quarter and full fiscal year 2023 reflects the company's resilience in a challenging market. While certain segments experienced declines, others showed growth, and the company's overall financial health remains robust. Investors and stakeholders can look forward to a cautious but optimistic outlook for the coming fiscal year.Explore the complete 8-K earnings release (here) from Agilent Technologies Inc for further details.This article first appeared on GuruFocus. | GuruFocus.com | "2023-11-20T21:41:24" | Agilent Technologies Inc (A) Reports Mixed Fiscal Year 2023 Results Amid Industry Challenges | https://finance.yahoo.com/news/agilent-technologies-inc-reports-mixed-214124027.html | 3656149b-9b19-370c-bef5-03fa9c016fd5 |
AAL | American Airlines Group Inc. (NASDAQ:AAL) shareholders should be happy to see the share price up 14% in the last month. But that can't change the reality that over the longer term (five years), the returns have been really quite dismal. Indeed, the share price is down 65% in the period. So is the recent increase sufficient to restore confidence in the stock? Not yet. Of course, this could be the start of a turnaround.While the last five years has been tough for American Airlines Group shareholders, this past week has shown signs of promise. So let's look at the longer term fundamentals and see if they've been the driver of the negative returns. View our latest analysis for American Airlines Group While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.American Airlines Group became profitable within the last five years. Most would consider that to be a good thing, so it's counter-intuitive to see the share price declining. Other metrics might give us a better handle on how its value is changing over time.Arguably, the revenue drop of 3.6% a year for half a decade suggests that the company can't grow in the long term. This has probably encouraged some shareholders to sell down the stock.You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).earnings-and-revenue-growthIt's probably worth noting that the CEO is paid less than the median at similar sized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. If you are thinking of buying or selling American Airlines Group stock, you should check out this free report showing analyst profit forecasts.Story continuesA Different PerspectiveWhile the broader market gained around 5.8% in the last year, American Airlines Group shareholders lost 12%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, longer term shareholders are suffering worse, given the loss of 10% doled out over the last five years. We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Even so, be aware that American Airlines Group is showing 3 warning signs in our investment analysis , and 2 of those are a bit unpleasant...For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.Join A Paid User Research SessionYou’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here | Simply Wall St. | "2023-05-18T15:00:59" | Positive earnings growth hasn't been enough to get American Airlines Group (NASDAQ:AAL) shareholders a favorable return over the last five years | https://finance.yahoo.com/news/positive-earnings-growth-hasnt-enough-150059997.html | eb848861-7f22-3cc3-856d-826e012477a7 |
AAL | American Airlines (AAL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.Therefore, the Zacks rating upgrade for American Airlines basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for American Airlines imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.Story continuesHarnessing the Power of Earnings Estimate RevisionsEmpirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>.Earnings Estimate Revisions for American AirlinesThis world's largest airline is expected to earn $2.71 per share for the fiscal year ending December 2023, which represents a year-over-year change of 442%.Analysts have been steadily raising their estimates for American Airlines. Over the past three months, the Zacks Consensus Estimate for the company has increased 15.6%.Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.You can learn more about the Zacks Rank here >>>The upgrade of American Airlines to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportAmerican Airlines Group Inc. (AAL) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research | Zacks | "2023-05-18T16:00:04" | American Airlines (AAL) Upgraded to Buy: Here's Why | https://finance.yahoo.com/news/american-airlines-aal-upgraded-buy-160004194.html | e8127d6d-d178-347a-8d03-5c228bab02a4 |
AAL | American Airlines CEO Robert Isom (left) speaking on stage at Skift Aviation Forum in Dallas, Texas, November 2022. SkiftHis tone was measured, but Judge Leo T. Sorokin made it clear he wasn’t buying the argument from American and JetBlue that their “Northeast Alliance” promoted competition and was good for flyers.Instead, in a 94-page ruling Friday afternoon, Sorokin laid out the history of the so-called NEA in which the two airlines share revenue and coordinate schedules and other practices in servicing New York and Boston. Sorokin said it harms consumers by effectively removing one competitor from the market.In short, Sorokin wrote: “Through the NEA, American and JetBlue cease to compete and, instead, operate as a single carrier in the northeast. That is the core of the relationship, and it is a naked assault on competition.”The U.S. Department of Justice sued to block the American Airlines-JetBlue Northeast Alliance in September 2021. On Friday, U.S. District Court Judge Sorokin said the partnership “substantially diminishes competition in the domestic market for air travel,” and ruled that the two airlines must unravel the partnership. An appeal is possible.Both American and JetBlue pushed back on the decision. American said, according to Reuters, “The court’s legal analysis is plainly incorrect and unprecedented for a joint venture.” It added that the alliance “has been a huge win for customers and anything but anticompetitive.” JetBlue said the “Northeast Alliance has been a huge win for customers” by extending the airline’s low fares “to more routes than would have been possible otherwise.”At a Skift event last November – before the the start of the trial – JetBlue President Joanna Geraghty defended the alliance to Edward Russell, Skift’s Transport editor and reporter: “If you look at the Northeast Alliance, Delta has doubled down in Boston. United has added a lot of capacity into Newark. And that’s all in response to what JetBlue and American are doing in the northeast. If that’s not a competitive response from legacy carriers that will drive competition and drive fares in a positive way, I don’t know what is.”Story continuesHere’s more background directly quoted from the court’s ruling:American and JetBlue are two of the four largest carriers operating in New York, and two of the largest three in Boston. Delta Air Lines is the only other carrier with a large presence in Boston.It is beyond dispute that, through June 2020, JetBlue vigorously and directly competed with American across all markets both carriers served.By 2020, JetBlue knew that Delta was mounting a challenge to its dominance in Boston.Around the same time, American was fretting about its operations in New York.In late 2019, the two carriers began discussing a possible lease, through which JetBlue would acquire temporary control over some of American’s slots at JFK… Talks between the carriers expanded to contemplate a broader domestic partnership focused on the northeast…The NEA was established and publicly announced on July 15, 2020….a relationship between American and JetBlue that includes codesharing, schedule coordination, revenue sharing, reciprocal loyalty benefits, and joint corporate customer benefits, all of which extend to most of the carriers’ flights to and from Logan, JFK, LaGuardia, and Newark (“the NEA airports”).[T]he record confirms what common sense suggests: in forming the NEA, American and JetBlue decided to stop competing and start cooperating with one another in the northeast.Airlines engaged in competition with one another would tactically respond to each other’s fares. They would consider launching new service to directly compete with a rival’s service on [origins and destinations]. They would not cede certain routes to a competitor. Within the NEA, American and JetBlue no longer adhere to these competitive practices with respect to one another. In that region, competition between them has effectively ceased.Though various executives claimed American and JetBlue continue to compete in some fashion within the northeast, there is no credible support for those claims. There is no evidence the defendants have engaged in meaningful competition with respect to fares, schedules, service, advertising, or anything else within the NEA region …It is abundantly clear to the Court that the defendants’ primary motivation in establishing the NEA was to strengthen their own competitive positions against Delta (and, to a lesser extent, United) in Boston and New York. Their own witnesses, business records, and submissions to the Court have repeatedly described this purpose.Essentially, American and JetBlue defend their partnership by broadly urging that “bigger is better,” and by claiming that they will be able to match or overtake (or, as they say, “compete with”) Delta only if they are permitted to stop competing with one another. That is not the kind of “competition” valued and protected by the Sherman Act.Watch: JetBlue President Joanna Geraghty at Skift Global Forum 2022Last fall, JetBlue’s President sat down with Airline Weekly Editor Ned Russell, when asked about the Northeast Alliance and the DOJ action, she told him “We’re confident that we will prevail.” Watch the video in full, below.Get breaking travel news and exclusive hotel, airline, and tourism research and insights at Skift.com. | Skift | "2023-05-22T06:30:00" | The Undoing of American and JetBlue’s Northeast Alliance – in 11 Quotes | https://finance.yahoo.com/news/undoing-american-jetblue-northeast-alliance-063000840.html | 8b3dd13e-3a3f-3a38-876c-101894dba320 |
AAL | Top airline stocks for the second quarter include Copa Holdings SA (CPA), Deutsche Lufthansa AG (DLAKY), and International Consolidated Airlines Group SA (BABWF). The share prices of all three have risen by more than 30% in the past year. Airline stocks, as represented by the U.S. Global Jets ETF (JETS) benchmark, have fallen 4% in the past 12 months, compared with a 3% gain for the S&P 500 Index.Continue reading | Investopedia | "2023-05-22T19:18:56" | Top Airline Stocks for Q2 2023 | https://finance.yahoo.com/m/d06c4f09-5914-374c-87b9-e995cc4f547d/top-airline-stocks-for-q2-2023.html | d06c4f09-5914-374c-87b9-e995cc4f547d |
AAL | Partnership extends UATP's widely accepted and seamless payment options to Flocash travel agency customers.WASHINGTON, May 23, 2023 /PRNewswire/ -- Flocash, the leading provider of travel payments and distribution in the Middle East and Africa, has partnered with UATP, a premier global payment network. Flocash's partnership with UATP will enable the thousands of travel agencies within its ecosystem to utilize UATP payment options, creating synergies with airlines in the region already using Flocash and UATP for B2B payments and reducing the overall cost of payments for those airlines.UATP is a global payment solution owned and operated by the world's airlines and accepted by thousands of merchants for air, rail and travel agency payments. UATP connects airlines to Alternative Forms of Payment which can expand reach and generate incremental sales globally. UATP offers easy-to-use data tools, DataStream(SM) and DataMine(SM), which provide comprehensive account details to Issuers and Corporate Subscribers for accurate travel management. UATP is accepted as a form of payment for corporate business travel worldwide by airlines, travel agencies and Amtrak; UATP accounts are issued by: Aeromexico, APG Airlines, Air Canada, Air New Zealand, Air Niugini, American Airlines, Austrian Airlines, China Eastern Airlines, Delta Air Lines, EL AL Israel Airlines, Etihad Airways, Frontier Airlines, GOL Linhas aereas inteligentes S.A., Hahn Air; Japan Airlines, Malaysia Airlines, Qantas Airways, Shandong Airlines, Transavia Airlines, TUIfly GmbH, Turkish Airline, United Airlines, and WestJet. AirPlus International issues the UATP-based Company Account for: British Airways and Lufthansa German Airlines. (PRNewsFoto/Universal Air Travel Plan, Inc.)The expanded partnership with Flocash represents the next step in UATP's continued global growth, specifically in the MEA region.For Flocash, which already works with UATP to process payments on behalf of several airline merchants in Africa, enabling many of its travel agency customers to use the UATP Network is a natural extension of its payment services and will create efficiencies that can directly and positively impact their profitability."Flocash is one of the most reliable payment services providers in the Middle East and Africa, and expanding our partnership with them was a key part of our regional growth strategy," said UATP's SVP Commercial Zach Ornelas. Partnering with Flocash allows travel agencies in their ecosystem to provide UATP accounts for payment and helps them reduce complexity while creating a more stable payment environment for the airlines and companies that work with them - and to better serve their customers."Flocash has been authorized to issue UATP accounts – including the UATP corporate charge card – to corporations and other businesses that meet their portfolio requirements. Those entities can use their UATP Accounts for payments to airlines, travel agencies and rail networks worldwide. Flocash will enjoy lower transaction and distribution costs, reduced fraud rates and access to industry-leading financial data.Story continues"By partnering with UATP, we give our travel agents a globally recognized, universally accepted form of payment, and create a linkage between our airline partners and the agencies selling their inventory," says Flocash Managing Director, Sirak Mussie. "We expect to uncover efficiencies and compound advantages across our ecosystem beyond transaction cost reduction, which is very important."Flocash is recognized as a cost-effective, one-stop payment solution for global and cross-border businesses in the new media, travel, payments and ecommerce industries seeking to reach markets in the Middle East and Africa. The company currently supports the most extensive collection of local payment options in the MEA region, including 200+ payment options, 5,000+ bank branches, 20,000+ cash points and 30+ currencies.For more information about the UATP and Flocash partnership or to speak with company executives, please contact Wendy Ward, UATP CMO, at wward@uatp.com.ABOUT UATPUATP is a global payment solution owned and operated by the world's airlines and accepted by thousands of merchants for air, rail and travel agency payments. UATP connects airlines to Alternative Forms of Payment which can expand reach and generate incremental sales globally. UATP offers easy-to-use data tools, DataStream® and DataMine® which provide comprehensive account details to Issuers and Corporate Account Holders for accurate travel management.Accepted as a form of payment for corporate business travel worldwide by airlines, travel agencies and Amtrak®; UATP accounts are issued by: Aeromexico; Air Canada (TSE: AC); Air China; Air New Zealand (ANZFF.PK); Air Niugini; American Airlines (NASDAQ: AAL); APG Airlines; Austrian Airlines; Avianca Airlines; BCD Travel; China Eastern Airlines (NYSE: CEA); Delta Air Lines (NYSE: DAL); EL AL Israel Airlines; Etihad Airways; Fareportal; Frontier Airlines; GOL Linhas aereas inteligentes S.A. (NYSE: GOL and Bovespa: GOLL4); Hahn Air; High Point Travel; Japan Airlines (9201:JP); JetBlue Airways; LATAM Airlines; Link Airways; Qantas Airways (QUBSF.PK); Shandong Airlines; Sichuan Airlines; Southwest Airlines; Sun Country Airlines; TUIfly GmbH; Turkish Airlines (ISE: THYAO); United Airlines (NASDQAQ: UAL) and WestJet. AirPlus International issues the UATP-based Company Account for Lufthansa German Airlines.About FlocashFlocash, www.flocash.com, is a leading provider of payment technology and distribution services to consumers, businesses, and financial institutions. We operate one of the largest networks of alternative payment channels for the travel industry. Our solutions are disrupting the travel sector by digitizing and automating the delivery and distribution of travel content to empower travel retailers and suppliers across 60 countries in the Middle East & Africa.Follow us on Twitter @Flocash, join the discussion on LinkedIn Travel Payments.Flocash Communications ContactBereket Getachew: bereket@flocash.com, +44 20 3287 6539CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/flocash-joins-uatp-payment-network-expanding-payment-options-to-travel-agencies-in-the-mea-region-301827355.htmlSOURCE Universal Air Travel Plan, Inc. (UATP) | PR Newswire | "2023-05-23T12:00:00" | Flocash Joins UATP Payment Network, Expanding Payment Options to Travel Agencies in the MEA Region | https://finance.yahoo.com/news/flocash-joins-uatp-payment-network-120000043.html | a972663a-48c5-328c-b9ce-a1c77945dee9 |
AAL | United Airlines (UAL) CEO Scott Kirby is putting a lot of capital to work for shareholders in new Boeing 737 Max airplanes, upgraded airport experiences, and added first-class seating.The last thing Kirby wants to see is America default on its debt in June after another contentious debt ceiling debate. That dire outcome would potentially lead to a US recession that harms returns on these key investments by United Airlines."The economy is balanced on a knife's edge," Kirby said on Yahoo Finance Live (video above). "When the Silicon Valley banking scare started, we saw a 15% overnight drop in business bookings, and that tells you the economy is very fragile.""That's what I am worried about with the debt ceiling," he added. "We don't need an unforced error in the economy — and this would just be an unforced error."A United Airlines jetliner taxis to a runway for take-off from Denver International Airport, Dec. 27, 2022. (AP Photo/David Zalubowski, File)Kirby says demand continues to be strong ahead of the busy Memorial Day travel weekend. But maintaining that momentum will be tough if the US is thrust into a self-created debt ceiling recession."If the debt ceiling crisis turns into a bigger crisis is where we are really impacted," Kirby added. "We just shouldn't take the risk — it's a silly, silly risk to think about letting that first domino fall."Kirby is hopeful politicians will come to a resolution in a timely manner.However, the contentious situation in D.C. isn't stopping United Airlines from making the major investments it views as necessary to beat the competition such as Jetblue (JBLU), Delta (DAL), and American Airlines (AAL).A woman walks to her car at an empty passenger drop off area at Denver International Airport as the coronavirus pandemic slows air travel on April 22, 2020 in Denver, Colorado. (Photo by Michael Ciaglo/Getty Images)United said Tuesday it will add 35 flights, six new routes, a dozen gates, and three clubs to Denver International Airport as part of a $1 billion investment plan. This summer, United will also double the total number of early morning departures and late evening arrivals in and out of Denver.The airline said it will offer more capacity from Denver than ever before, with over 60,000 departing seats per day.Story continues"It's just a great, growing city," Kirby said on the thinking behind the Denver investment.Brian Sozzi is Yahoo Finance's Executive Editor. Follow Sozzi on Twitter @BrianSozzi and on LinkedIn. Tips on the banking crisis? Email brian.sozzi@yahoofinance.comClick here for the latest stock market news and in-depth analysis, including events that move stocksRead the latest financial and business news from Yahoo Finance | Yahoo Finance | "2023-05-23T15:41:01" | United CEO on debt ceiling, new $1 billion Denver investment | https://finance.yahoo.com/news/united-ceo-on-debt-ceiling-new-1-billion-denver-investment-154101665.html | 3510035c-147f-47f8-99b5-90b353082227 |
AAL | (Reuters) - American Airlines Group Inc's Chief Financial Officer Devon May said on Thursday the court ruling on the Northeast Alliance with JetBlue Airways Corp will not have any impact on the carrier's earnings.American Airlines and JetBlue announced the creation of the Northeast Alliance (NEA) in July 2020 to coordinate flights and pool revenue while competing against Delta Air Lines and United Airlines, that dominate the New York-area and Boston markets.Last week, a federal judge ruled for both carriers to end the alliance saying the partnership "substantially diminishes competition in the domestic market for air travel"."It's a big deal for our New York strategy. It is not something that's meaningful to our earnings," May said on Thursday at the Wolfe transportation and industrials conference, adding that he doesn't expect the NEA ruling to have any impact on the carrier's macro capacity.(Reporting by Aishwarya Nair in Bengaluru; Editing by Shounak Dasgupta) | Reuters | "2023-05-25T15:46:26" | American Airlines flags no earnings impact from NEA ruling | https://finance.yahoo.com/news/american-airlines-flags-no-earnings-154626258.html | c1bbffa1-e786-3ad8-8443-1e2f5a65315c |
AAL | In the past week, Ryanair Holdings RYAAY reported a narrower-than-expected loss for the fourth quarter of fiscal 2023. Revenues also beat the consensus mark and increased year over year, owing to upbeat traffic volumes.American Airlines AAL was also in the news, courtesy of its agreement in principle with its pilot union, Allied Pilots Association. Meanwhile, AAL’s Northeast Alliance with JetBlue Airways JBLU ran into rough weather following a court ruling to end the partnership. Delta Air Lines DAL also grabbed headlines courtesy of its decision to appoint a new chief operating officer.Recap of the Past Week’s Most Important Stories1. Ryanair reported fourth-quarter fiscal 2023 (ended Mar 31, 2023) loss of 73 cents per share (excluding a penny from non-recurring items), narrower than the Zacks Consensus Estimate of a loss of 99 cents. In the year-ago reported quarter, RYAAY had incurred a loss of 98 cents per share. Revenues of $1,981.5 million beat the Zacks Consensus Estimate of $1,908.7 million. Revenues improved year over year, driven by upbeat passenger volumes.On the back of the buoyant traffic scenario, RYAAY’s profit after tax was €1.42 billion in fourth-quarter fiscal 2023 against a net loss of €355 million incurred a year ago. Ryanair expects traffic for fiscal 2024 to be 185 million.Currently, Ryanair carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.2. The Allied Pilots Association, which represents 15,000 plus pilots at AAL, reached an agreement in principle with the company. If the collective bargaining agreement materializes, American Airlines pilots would be eligible for a 21% pay raise this year. Further details will be available shortly.3. American Airlines and JetBlue received a major setback when a federal judge ordered the companies to terminate their alliance in the Northeast as it was anti-competitive. The verdict is in line with the Justice Department’s opinion. The Justice Department’s antitrust suit, filed more than a year ago, accused the alliance of stifling competition. The judge ordered the companies to end the alliance within 30 days of the ruling. Both carriers are likely to challenge the decision. In fact, AAL’s management said that the ruling will not impact its earnings performance.Story continues4. Delta announced that it will get a new chief operating officer from Jun 12. This Atlanta-based carrier appointed Mike Spanos for the new role. Spanos has more than two decades of work experience and has been associated with many big companies. Most recently, he was with Six Flags Entertainment SIX as its president and CEO.PerformanceThe following table shows the price movement of the major airline players over the past week and during the last six months.Zacks Investment ResearchImage Source: Zacks Investment ResearchThe table above shows that stocks exhibited a mixed trend with respect to price over the past week. However, the gains were muted in nature. As a result, the NYSE ARCA Airline Index gained marginally over the past week. Over the course of past six months, the NYSE ARCA Airline Index has appreciated 3.9%.What’s Next in the Airline Space?Investors will be looking forward to further updates on the alliance between American Airlines and JetBlue.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportRyanair Holdings PLC (RYAAY) : Free Stock Analysis ReportDelta Air Lines, Inc. (DAL) : Free Stock Analysis ReportJetBlue Airways Corporation (JBLU) : Free Stock Analysis ReportAmerican Airlines Group Inc. (AAL) : Free Stock Analysis ReportSix Flags Entertainment Corporation New (SIX) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research | Zacks | "2023-05-26T13:45:00" | Airline Stock Roundup: RYAAY's Q4 Loss, AAL's Labor Deal & More | https://finance.yahoo.com/news/airline-stock-roundup-ryaays-q4-134500453.html | 1d2b4b49-e4b7-3b73-8565-aabd81e0847d |
End of preview. Expand
in Dataset Viewer.
Dataset Card for "news-sp500"
Dataset Summary
The news-sp500 dataset provides news articles related to companies in the S&P 500 index.
Supported Tasks and Leaderboards
The dataset can be used for various natural language processing tasks such as text classification, sentiment analysis, information extraction, etc. It does not have a specific leaderboard associated with it.
Languages
The dataset contains news articles in multiple languages.
Dataset Structure
Data Instances
The dataset consists of [1563] data instances.
Data Fields
- symbol (string): A string representing the ticker symbol or abbreviation used to identify the company.
- body (string): The main content of the news article.
- publisher (string): The name of the publisher or news agency.
- publish_time (timestamp[ns, tz=GMT]): A timestamp indicating the publication time of the news article in GMT timezone.
- title (string): The title or headline of the news article.
- url (string): The URL or link to the original news article.
- uuid (string): A unique identifier for the news article.
Data Splits
The dataset consists of a single split called train.
Dataset Creation
Curation Rationale
The news-sp500 dataset was created to provide a collection of news articles related to companies in the S&P 500 index for research and analysis purposes.
Source Data
Initial Data Collection and Normalization
The data was collected from various online news sources and normalized for consistency.
Annotations
Annotation process
[N/A]
Who are the annotators?
[N/A]
Personal and Sensitive Information
[N/A]
Considerations for Using the Data
Social Impact of Dataset
[N/A]
Discussion of Biases
[N/A]
Other Known Limitations
[N/A]
Additional Information
Dataset Curators
The news-sp500 dataset was collected by https://edarchimbaud.substack.com.
Licensing Information
The news-sp500 dataset is licensed under the MIT License.
Citation Information
https://edarchimbaud.substack.com, news-sp500 dataset, GitHub repository, https://github.com/edarchimbaud
Contributions
Thanks to @edarchimbaud for adding this dataset.
- Downloads last month
- 20